

## Publications for Jacob George

### 2019

- Li, G., Chan, Y., Sukjamnong, S., Anwer, A., Vindin, H., Padula, M., Zakarya, R., George, J., Oliver, B., Saad, S., et al (2019). A Mitochondrial Specific Antioxidant Reverses Metabolic Dysfunction and Fatty Liver Induced by Maternal Cigarette Smoke in Mice. *Nutrients*, 11(7), 1-14. <a href="http://dx.doi.org/10.3390/nu11071669">[More Information]</a>
- Metwally, M., Bayoumi, A., Romero-Gomez, M., Thabet, K., John, M., Adams, L., Huo, X., Aller, R., Garcia-Monzon, C., Arias-Loste, M., Liddle, C., Qiao, L., George, J., Eslam, M., et al (2019). A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR. *Journal of Hepatology*, 70(3), 494-500. <a href="http://dx.doi.org/10.1016/j.jhep.2018.10.021">[More Information]</a>
- El Sharkawy, R., Bayoumi, A., Metwally, M., Mangia, A., Berg, T., Romero-Gomez, M., Abate, M., Irving, W., Sheridan, D., Dore, G., Latchoumanin, O., Thabet, K., Najim, M., Douglas, M., Liddle, C., Qiao, L., George, J., Eslam, M., et al (2019). A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF- $\beta$ 1 dependent mechanisms. *Scientific Reports*, 9(1), 1-10. <a href="http://dx.doi.org/10.1038/s41598-018-35736-2">[More Information]</a>
- Daniels, S., Eslam, M., Leeming, D., Hashem, A., Nielsen, M., Krag, A., Karsdal, M., Grove, J., Neil Guha, I., Kawaguchi, T., George, J., et al (2019). ADAPT: An algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. *Hepatology*, 69(3), 1075-1086. <a href="http://dx.doi.org/10.1002/hep.30163">[More Information]</a>
- Hu, L., Su, L., Dong, Z., Wu, Y., Lv, Y., George, J., Wang, J. (2019). AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the  $\frac{1}{2}$ BDL rat model. *Journal of Molecular Medicine*, 97(3), 423-434. <a href="http://dx.doi.org/10.1007/s00109-019-01746-4">[More Information]</a>
- Eslam, M., Sanyal, A., George, J. (2019). Are Non-alcoholic Fatty Liver Disease and Alcoholic Fatty Liver Disease More Than Just Semantics? *Gastroenterology*, 157(3), 590-593. <a href="http://dx.doi.org/10.1053/j.gastro.2019.05.064">[More Information]</a>
- Strasser, S., Thompson, A., Roberts, S., George, J. (2019). Clinical Cases in Hepatitis: Towards improving liver disease management in Australia. *Journal of Gastroenterology and Hepatology*, 34, 5-15. <a href="http://dx.doi.org/10.1111/jgh.14720">[More Information]</a>
- Alavi, M., Law, B., Valerio, H., Grebely, J., Amin, J., Hajarizadeh, B., Selvey, C., George, J., Dore, G. (2019). Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. *Journal of Hepatology*, 71(2), 281-288. <a href="http://dx.doi.org/10.1016/j.jhep.2019.04.014">[More Information]</a>
- Parker, H., Cohn, J., O'Connor, H., Garg, M., Caterson, I., George, J., Johnson, N. (2019). Effect of Fish Oil Supplementation on Hepatic and Visceral Fat in Overweight Men: A Randomized Controlled Trial. *Nutrients*, 11(2), 1-15. <a href="http://dx.doi.org/10.3390/nu11020475">[More Information]</a>
- Younossi, Z., Stepanova, M., Ong, J., Yilmaz, Y., Duseja, A., Eguchi, Y., Kassas, M., Jacobson, I., Bugianesi, E., George, J., et al (2019). Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients with Non-alcoholic and Alcohol-Related Fatty Liver Disease. *Clinical Gastroenterology and Hepatology*, 17(8), 1625-1633. <a href="http://dx.doi.org/10.1016/j.cgh.2018.11.033">[More Information]</a>
- Wei, L., Jia, J., Wang, F., Niu, J., Zhao, X., Mu, S., Liang, L., Wang, Z., Hwang, P., George, J., et al (2019). Efficacy and safety of elbasvir/grazoprevir in participants with HCV genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: final results from the randomized C-CORAL study. *Journal of Gastroenterology and Hepatology*, 34(1), 12-21. <a href="http://dx.doi.org/10.1111/jgh.14509">[More Information]</a>
- Sheppard-Law, S., Zablotska-Manos, I., Kermeen, M., Holdaway, S., Lee, A., Zekry, A., Dore, G., George, J., Maher, L. (2019). Factors associated with non-adherence to HBV antiviral therapy. *Antiviral Therapy*, 22(1), 53-60. <a href="http://dx.doi.org/10.3851/IMP3219">[More Information]</a>
- Eslam, M., George, J. (2019). Genetic Insights for Drug Development in NAFLD. *Trends In Pharmacological Sciences*, 40(7), 506-516. <a href="http://dx.doi.org/10.1016/j.tips.2019.05.002">[More Information]</a>
- Douglas, M., Tay, E., Eden, J., George, J. (2019). Hepatitis C Virus Genotype 8 - successful treatment with sofosbuvir/velpatasvir. *The Journal of Infectious Diseases*, 220(4), 720-722. <a href="http://dx.doi.org/10.1093/infdis/jiz155">[More Information]</a>
- Wijaya, R., Read, S., Schibeci, S., Eslam, M., Azardaryany, M., El-Khobar, K., van der Poorten, D., Lin, R., Yuen, L., Lam, V., George, J., Douglas, M., Ahlenstiel, G. (2019). KLRG1+ natural killer cells exert a novel antifibrotic function in chronic hepatitis B. *Journal of Hepatology*, 71(2), 252-264. <a href="http://dx.doi.org/10.1016/j.jhep.2019.03.012">[More Information]</a>
- Younossi, Z., Stepanova, M., Ong, J., Jacobson, I., Bugianesi, E., Duseja, A., Eguchi, Y., Wong, V., Negro, F., Yilmaz, Y., George, J., et al (2019). Non-alcoholic Steatohepatitis is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. *Clinical Gastroenterology and Hepatology*, 17(4), 748-755. <a href="http://dx.doi.org/10.1016/j.cgh.2018.05.057">[More Information]</a>
- Walker, S., Wankell, M., Ho, V., White, R., Deo, N., Devine, C., Dewdney, B., Bhathal, P., Govaere, O., Roskams, T., Qiao, L., George, J., Hebbard, L. (2019). Targeting mTOR and Src restricts hepatocellular carcinoma growth in a novel murine liver cancer model. *PloS One*, 14(2), e0212860. <a href="http://dx.doi.org/10.1371/journal.pone.0212860">[More Information]</a>

Wong, M., Huang, J., George, J., Huang, J., Leung, C., Eslam, M., Chan, H., Ng, S. (2019). The changing epidemiology of liver diseases in the Asia-Pacific region. *Nature Reviews. Gastroenterology and Hepatology*, 16(1), 57-73. <a href="http://dx.doi.org/10.1038/s41575-018-0055-0">[More Information]</a>

Kazankov, K., Jorgensen, S., Thomsen, K., Moller, H., Vilstrup, H., George, J., Schuppan, D., Gronbaek, H. (2019). The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *Nature Reviews. Gastroenterology and Hepatology*, 16(3), 145-159. <a href="http://dx.doi.org/10.1038/s41575-018-0082-x">[More Information]</a>

Gupta, S., Read, S., Shackel, N., Hebbard, L., George, J., Ahlenstiel, G. (2019). The Role of Micronutrients in the Infection and Subsequent Response to Hepatitis C Virus. *Cells*, 8(6), 1-20. <a href="http://dx.doi.org/10.3390/cells8060603">[More Information]</a>

## 2018

Kawaguchi, T., Tokushige, K., Hyogo, H., Aikata, H., Nakajima, T., Ono, M., Kawanaka, M., Sawada, K., Imajo, K., Honda, K., George, J., et al (2018). A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. *Scientific Reports*, 8(1), 1-13. <a href="http://dx.doi.org/10.1038/s41598-018-28650-0">[More Information]</a>

Kabir, T., Ganda, C., Brown, R., Beveridge, D., Richardson, K., Chaturvedi, V., Candy, P., Epis, M., Wintle, L., Kalinowski, F., George, J., et al (2018). A miR-7/GAS6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma. *Hepatology*, 67(1), 216-231. <a href="http://dx.doi.org/10.1002/hep.29478">[More Information]</a>

El Sharkawy, R., Thabet, K., Lampertico, P., Petta, S., Mangia, A., Berg, T., Metwally, M., Bayoumi, A., Douglas, M., Khan, A., et al (2018). A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. *Alimentary Pharmacology and Therapeutics*, 48(5), 564-573. <a href="http://dx.doi.org/10.1111/apt.14866">[More Information]</a>

Zhou, G., Latchoumanin, O., Hebbard, L., Duan, W., Liddle, C., George, J., Qiao, L. (2018). Aptamers as targeting ligands and therapeutic molecules for overcoming drug resistance in cancers. *Advanced Drug Delivery Reviews*, 134, 107-121. <a href="http://dx.doi.org/10.1016/j.addr.2018.04.005">[More Information]</a>

Younossi, Z., Loomba, R., Rinella, M., Bugianesi, E., Marchesini, G., Neuschwander-Tetri, B., Serfaty, L., Negro, F., George, J., et al (2018). Current and Future Therapeutic Regimens for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. *Hepatology*, 68(1), 361-371. <a href="http://dx.doi.org/10.1002/hep.29724">[More Information]</a>

Younossi, Z., Loomba, R., Anstee, Q., Rinella, M., Bugianesi, E., Marchesini, G., Neuschwander-Tetri, B., Serfaty, L., Negro, F., Caldwell, S., George, J., et al (2018). Diagnostic Modalities for Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis and Associated Fibrosis. *Hepatology*, 68(1), 349-360. <a href="http://dx.doi.org/10.1002/hep.29721">[More Information]</a>

El Sharkawy, R., George, J., Eslam, M. (2018). Editorial: STAT-4 polymorphism - a tool to personalise clinical practice in chronic HBV infection Authors' reply. *Alimentary*

*Pharmacology and Therapeutics*, 48(7), 769-770. <a href="http://dx.doi.org/10.1111/apt.14940">[More Information]</a>

Eslam, M., George, J. (2018). Editorial: weight change, liver histology and the metabolic effects of obeticholic acid in NASH. *Alimentary Pharmacology and Therapeutics*, 47(7), 1038-1039. <a href="http://dx.doi.org/10.1111/apt.14547">[More Information]</a>

Roberts, S., Lim, R., Strasser, S., Nicoll, A., Gazzola, A., Mitchell, J., Siow, W., Khoo, T., Hamarneh, Z., Weltman, M., George, J., et al (2018). Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy. *Clinical Gastroenterology and Hepatology*, 16(2), 268-277. <a href="http://dx.doi.org/10.1016/j.cgh.2017.09.063">[More Information]</a>

George, J., Burnevich, E., Sheen, I., Heo, J., Van Kinh, N., Tanwandee, T., Cheng, P., Kim, D., Tak, W., Kizhlo, S., et al (2018). Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection. *Hepatology Communications*, 2(5), 595-606. <a href="http://dx.doi.org/10.1002/hep4.1177">[More Information]</a>

Vilar-Gomez, E., Calzadilla-Bertot, L., Wong, V., Castellanos, M., de la Fuente, R., Metwally, M., Eslam, M., Gonzalez-Fabian, L., Alvarez-Quinones Sanz, M., Conde-Martin, A., George, J., et al (2018). Fibrosis Severity as a Determinant of Cause-specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease. *Gastroenterology*, 155(2), 443-457.e17. <a href="http://dx.doi.org/10.1053/j.gastro.2018.04.034">[More Information]</a>

Younossi, Z., Anstee, Q., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., Bugianesi, E. (2018). Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. *Nature Reviews. Gastroenterology and Hepatology*, 15(1), 11-20. <a href="http://dx.doi.org/10.1038/nrgastro.2017.109">[More Information]</a>

Katoonizadeh, A., Motamed-Gorji, N., Sharafkhan, M., Ostovaneh, M., Esmaili, S., Eslami, L., Gharravi, A., Khoshnia, M., Shayanrad, A., Katouli, F., George, J., et al (2018). Intra-familial Transmission of Chronic Hepatitis B Infection: A Large Population-Based Cohort Study in Northern Iran. *Archives of Iranian Medicine*, 21(10), 436-442.

Sublette, V., Smith, S., George, J., McCaffery, K., Douglas, M. (2018). Listening to both sides: A qualitative comparison between patients with hepatitis C and their healthcare professionals' perceptions of the facilitators and barriers to hepatitis C treatment adherence and completion. *Journal of Health Psychology*, 23(13), 1720-1731. <a href="http://dx.doi.org/10.1177/1359105316669858">[More Information]</a>

Alavi, M., Grebely, J., Hajarizadeh, B., Amin, J., Larney, S., Law, M., George, J., Degenhardt, L., Dore, G. (2018). Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012. *BMC Infectious Diseases*, 18(1), 215. <a href="http://dx.doi.org/10.1186/s12879-018-3110-0">[More Information]</a>

George, J., Anstee, Q., Ratziu, V., Sanyal, A. (2018). NAFLD: The evolving landscape. *Journal of Hepatology*, 68(2), 227-229. <a href="http://dx.doi.org/10.1016/j.jhep.2017.11.016">[More Information]</a>

Mahady, S., George, J. (2018). Predicting the future burden of NAFLD and NASH. *Journal of Hepatology*, 69(4), 774-775. <a href="http://dx.doi.org/10.1016/j.jhep.2018.06.025">[More Information]</a>

Laursen, T., Siggard, C., Kazankov, K., Sandahl, T., Moller, H., Ong, A., Douglas, M., George, J., Tarp, B., Kristensen, L., et al (2018). Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology. *Scandinavian Journal of Gastroenterology*, 53(8), 986-993. <a href="http://dx.doi.org/10.1080/00365521.2018.1481996">[More Information]</a>

McCaughan, G., Thwaites, P., Roberts, S., Strasser, S., Mitchell, J., Morales, B., Mason, S., Gow, P., Wigg, A., George, J., et al (2018). Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD  $\geq$  15). *Alimentary Pharmacology and Therapeutics*, 47(3), 401-411. <a href="http://dx.doi.org/10.1111/apt.14404">[More Information]</a>

Laursen, T., Wong, G., Kazankov, K., Sandahl, T., Moller, H., Hamilton-Dutoit, S., George, J., Chan, H., Gronbaek, H. (2018). Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. *Journal of Gastroenterology and Hepatology*, 33(2), 484-491. <a href="http://dx.doi.org/10.1111/jgh.13849">[More Information]</a>

Read, S., Parnell, G., Booth, D., Douglas, M., George, J., Ahlenstiel, G. (2018). The antiviral role of zinc and metallothioneins in hepatitis C infection. *Journal of Viral Hepatitis*, 25(5), 491-501. <a href="http://dx.doi.org/10.1111/jvh.12845">[More Information]</a>

Alavi, M., Janjua, N., Chong, M., Grebely, J., Aspinall, E., Innes, H., Valerio, H., Hajarizadeh, B., Hayes, P., Krajdén, M., George, J., et al (2018). The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: an international study. *Journal of Hepatology*, 68(3), 393-401. <a href="http://dx.doi.org/10.1016/j.jhep.2017.10.019">[More Information]</a>

Simpson, S., Raubenheimer, D., Cogger, V., Macia, L., Solon-Biet, S., Le Couteur, D., George, J. (2018). The nutritional geometry of liver disease including non-alcoholic fatty liver disease (NAFLD). *Journal of Hepatology*, 68(2), 316-325. <a href="http://dx.doi.org/10.1016/j.jhep.2017.10.005">[More Information]</a>

Alzahrani, B., Iseli, T., Ramezani-Moghadam, M., Ho, V., Wankell, M., Sun, E., Qiao, L., George, J., Hebbard, L. (2018). The role of AdipoR1 and AdipoR2 in liver fibrosis. *Biochimica et Biophysica Acta - Molecular Basis of Disease*, 1864 (3), 700-708. <a href="http://dx.doi.org/10.1016/j.bbadis.2017.12.012">[More Information]</a>

Zeuzem, S., Serfaty, L., Vierling, J., Cheng, W., George, J., Sperl, J., Strasser, S., Kumada, H., Hwang, P., Robertson, M., et al (2018). The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. *Journal of Gastroenterology*, 53(5), 679-688. <a href="http://dx.doi.org/10.1007/s00535-018-1429-3">[More Information]</a>

Alavi, M., Janjua, N., Chong, M., Grebely, J., Aspinall, E., Innes, H., Valerio, H., Hajarizadeh, B., Hayes, P., Krajdén, M., George, J., et al (2018). Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: an international comparison. *Journal of Viral Hepatitis*, 25(5), 473-

481. <a href="http://dx.doi.org/10.1111/jvh.12837">[More Information]</a>

Robotin, M., Masgoret, X., Porwal, M., Goldsbury, D., Khoo, C., George, J. (2018). Using a chronic hepatitis B Registry to support population-level liver cancer prevention in Sydney, Australia. *Clinical Epidemiology*, 10, 41-49. <a href="http://dx.doi.org/10.2147/CLEP.S146275">[More Information]</a>

Sheppard-Law, S., Zablotska-Manos, I., Kermeen, M., Holdaway, S., Lee, A., George, J., Zekry, A., Maher, L. (2018). Utilisation of hepatocellular carcinoma screening in Australians at risk of hepatitis B virus-related carcinoma and prescribed anti-viral therapy. *Journal of Clinical Nursing*, 27(13-14), 2673-2683. <a href="http://dx.doi.org/10.1111/jocn.14367">[More Information]</a>

## 2017

Gauthiez, E., Habfast-Robertson, I., Rueger, S., Kutalik, Z., Aubert, V., Berg, T., Cerny, A., Gorgievski, M., George, J., Heim, M., et al (2017). A systematic review and meta-analysis of HCV clearance. *Liver International*, 37(10), 1431-1445. <a href="http://dx.doi.org/10.1111/liv.13401">[More Information]</a>

Baatarkhuu, O., Lee, H., George, J., Munkh-Orrshikh, D., Enkhtuvshin, B., Ariunaa, S., Eslam, M., Ahn, S., Han, K., Kim, D. (2017). Acute hepatitis A, B and C but not D is still prevalent in Mongolia: a time trend analysis. *Clinical and Molecular Hepatology*, 23(2), 147-153. <a href="http://dx.doi.org/10.3350/cmh.2016.0055">[More Information]</a>

Obeid, S., Wankell, M., Charrez, B., Sternberg, J., Kreuter, R., Esmaili, S., Ramezani-Moghadam, M., Devine, C., Read, S., Bhathal, P., Ahlenstiel, G., Qiao, L., George, J., Hebbard, L., et al (2017). Adiponectin confers protection from acute colitis and restricts a B cell immune response. *Journal of Biological Chemistry*, 292(16), 6569-6582. <a href="http://dx.doi.org/10.1074/jbc.M115.712646">[More Information]</a>

Hashida, R., Kawaguchi, T., Bekki, M., Omoto, M., Matsuse, H., Nago, T., Takano, Y., Ueno, T., Koga, H., George, J., et al (2017). Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. *Journal of Hepatology*, 66(1), 142-152. <a href="http://dx.doi.org/10.1016/j.jhep.2016.08.023">[More Information]</a>

Zhou, G., Latchoumanin, O., Bagdesar, M., Hebbard, L., Duan, W., Liddle, C., George, J., Qiao, L. (2017). Aptamer-based therapeutic approaches to target cancer stem cells. *Theranostics*, 7(16), 3948-3961. <a href="http://dx.doi.org/10.7150/thno.20725">[More Information]</a>

Mahady, S., Macaskill, P., Craig, J., Wong, G., Chu, W., Chan, H., George, J., Wong, V. (2017). Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of Fibrosis. *Clinical Gastroenterology and Hepatology*, 15(9), 1453-1460. <a href="http://dx.doi.org/10.1016/j.cgh.2017.02.031">[More Information]</a>

Huo, X., Han, S., Wu, G., Latchoumanin, O., Zhou, G., Qiao, L., George, J., Hebbard, L. (2017). Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: Implications for tumorigenesis, disease progression, and liver cancer stem cells. *Molecular Cancer*, 16(1), 1-10. <a href="http://dx.doi.org/10.1186/s12943-017-0734-4">[More Information]</a>

- Keating, S., Hackett, D., Parker, H., Way, K., O'Connor, H., Salis (nee Sainsbury), A., Baker, M., Chuter, V., Caterson, I., George, J., Johnson, N. (2017). Effect of resistance training on liver fat and visceral adiposity in adults with obesity: A randomized controlled trial. *Hepatology Research*, 47(7), 622-631. <a href="http://dx.doi.org/10.1111/hepr.12781">[More Information]</a>
- Riisgaard-Hansen, S., St George, A., Kazankov, K., Bauman, A., George, J., Griek, H., Müller, H. (2017). Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease. *Scandinavian Journal of Clinical and Laboratory Investigation*, 77(7), 498-504. <a href="http://dx.doi.org/10.1080/00365513.2017.1346823">[More Information]</a>
- Mahady, S., Wong, G., Turner, R., Mitchell, P., Macaskill, P., Craig, J., George, J. (2017). Elevated Liver Enzymes and Mortality in Older Individuals: A Prospective Cohort Study. *Journal of Clinical Gastroenterology*, 51(5), 439-445. <a href="http://dx.doi.org/10.1097/MCG.0000000000000622">[More Information]</a>
- Sabag, A., Way, K., Keating, S., Sultana, R., O'Connor, H., Baker, M., Chuter, V., George, J., Johnson, N. (2017). Exercise and ectopic fat in type 2 diabetes: a systematic review and meta-analysis. *Diabetes and Metabolism*, 43(3), 195-210. <a href="http://dx.doi.org/10.1016/j.diabet.2016.12.006">[More Information]</a>
- Sheppard-Law, S., Zablotka-Manos, I., Kermeen, M., Holdaway, S., Lee, A., Zekry, A., Dore, G., George, J., Maher, L. (2017). Factors associated with HBV virological breakthrough. *Antiviral Therapy*, 22(1), 53-60. <a href="http://dx.doi.org/10.3851/IMP3087">[More Information]</a>
- Lim, L., Thompson, A., Patterson, S., George, J., Strasser, S., Lee, A., Sievert, W., Nicoll, A., Desmond, P., Roberts, S., et al (2017). Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy. *Liver International*, 37(6), 827-835. <a href="http://dx.doi.org/10.1111/liv.13331">[More Information]</a>
- Scott, C., Cha, K., Ngai, J., Jiang, C., Cheng, K., Stokes, R., Ho, K., George, J., Gonzalez, F., Gunton, J. (2017). Hepatic Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) regulates metabolism in mice. *PloS One*, 12(11), 1-14. <a href="http://dx.doi.org/10.1371/journal.pone.0186543">[More Information]</a>
- Waziry, R., Hajarizadeh, B., Grebely, J., Amin, J., Law, M., Danta, M., George, J., Dore, G. (2017). Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. *Journal of Hepatology*, 67(6), 1204-1212. <a href="http://dx.doi.org/10.1016/j.jhep.2017.07.025">[More Information]</a>
- Eslam, M., McLeod, D., Kelaeng, K., Mangia, A., Berg, T., Thabet, K., Irving, W., Dore, G., Sheridan, D., Gronbaek, H., Booth, D., Weltman, M., Douglas, M., Liddle, C., George, J., et al (2017). IFN-(lambda)3, not IFN-(lambda)4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. *Nature Genetics*, 49(5), 795-800. <a href="http://dx.doi.org/10.1038/ng.3836">[More Information]</a>
- Sublette, V., Smith, S., George, J., McCaffery, K., Douglas, M. (2017). Listening to both sides: A qualitative comparison between patients with hepatitis C and their healthcare professionals' perceptions of the facilitators and barriers to hepatitis C treatment adherence and completion. *Journal of Health Psychology*, 22(10), 1300-1311. <a href="http://dx.doi.org/10.1177/1359105315626786">[More Information]</a>
- Robotin, M., Porwal, M., Hopwood, M., Nguyen, D., Sze, M., Treloar, C., George, J. (2017). Listening to the consumer voice: developing multilingual cancer information resources for people affected by liver cancer. *Health Expectations*, 20(1), 171-182. <a href="http://dx.doi.org/10.1111/hex.12449">[More Information]</a>
- Petta, S., Eslam, M., Valenti, L., Bugianesi, E., Barbara, M., Camma, C., Porzio, M., Rosso, C., Fargion, S., George, J., et al (2017). Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. *Liver International*, 37(9), 1389-1396. <a href="http://dx.doi.org/10.1111/liv.13397">[More Information]</a>
- Keating, S., Parker, H., Hickman, I., Gomersall, S., Wallen, M., Coombes, J., Macdonald, G., George, J., Johnson, N. (2017). NAFLD in clinical practice: Can simple blood and anthropometric markers be used to detect change in liver fat measured by 1H-MRS? *Liver International*, 37(12), 1907-1915. <a href="http://dx.doi.org/10.1111/liv.13488">[More Information]</a>
- Wu, G., Wilson, G., George, J., Liddle, C., Hebbard, L., Qiao, L. (2017). Overcoming treatment resistance in cancer: Current understanding and tactics. *Cancer Letters*, 387, 69-76. <a href="http://dx.doi.org/10.1016/j.canlet.2016.04.018">[More Information]</a>
- Mahady, S., Gale, J., Macaskill, P., Craig, J., George, J. (2017). Prevalence of elevated alanine transaminase in Australia and its relationship to metabolic risk factors: A cross-sectional study of 9,447 people. *Journal of Gastroenterology and Hepatology*, 32(1), 169-176. <a href="http://dx.doi.org/10.1111/jgh.13434">[More Information]</a>
- Lubel, J., Strasser, S., Stuart, K., Dore, G., Thompson, A., Pianko, S., Bollipo, S., Mitchell, J., Fragomeli, V., Jones, T., George, J., et al (2017). Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir and ribavirin for hepatitis C genotype 1 final results of the REVITAL study. *Antiviral Therapy*, 22(8), 699-710. <a href="http://dx.doi.org/10.3851/IMP3168">[More Information]</a>
- Han, S., Latchoumanin, O., Wu, G., Zhou, G., Hebbard, L., George, J., Qiao, L. (2017). Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors. *Cancer Letters*, 390, 188-200. <a href="http://dx.doi.org/10.1016/j.canlet.2016.12.037">[More Information]</a>
- Gane, E., DeJesus, E., Janczewska, E., George, J., Diago, M., Da Silva, M., Reesink, H., Nikitin, I., Hinrichsen, H., Bourgeois, S., et al (2017). Simeprevir with peginterferon (alpha)-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: An open-label, rollover study. *BMC Infectious Diseases*, 17(1), 1-13. <a href="http://dx.doi.org/10.1186/s12879-017-2444-3">[More Information]</a>
- Waziry, R., Grebely, J., Amin, J., Alavi, M., Hajarizadeh, B., George, J., Matthews, G., Law, M., Dore, G. (2017). Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014). *Hepatology Communications*, 1(8), 736-747. <a href="http://dx.doi.org/10.1002/hep4.1073">[More Information]</a>
- Rademaker, M., Gupta, M., Andrews, M., Armour, K., Baker,

C., Foley, P., Gebauer, K., George, J., Rubel, D., Sullivan, J. (2017). The Australasian Psoriasis Collaboration view on methotrexate for psoriasis in the Australasian setting. *Australasian Journal of Dermatology*, 58(3), 166-170. <a href="http://dx.doi.org/10.1111/ajd.12521">[More Information]</a>

Simpson, S., Le Couteur, D., James, D., George, J., Gunton, J., Solon-Biet, S., Raubenheimer, D. (2017). The Geometric Framework for Nutrition as a tool in precision medicine. *Nutrition and Healthy Aging*, 4(3), 217-226. <a href="http://dx.doi.org/10.3233/NHA-170027">[More Information]</a>

Thabet, K., Chan, H., Petta, S., Mangia, A., Berg, T., Boonstra, A., Brouwer, W., Abate, M., Wong, V., Nazmy, M., Liddle, C., George, J., Eslam, M., et al (2017). The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. *Hepatology*, 65(6), 1840-1850. <a href="http://dx.doi.org/10.1002/hep.29064">[More Information]</a>

John, M., Metwally, M., Mangia, A., Romero-Gomez, M., Berg, T., Sheridan, D., George, J., Eslam, M. (2017). TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C. *Gastroenterology*, 153(5), 1448-1449. <a href="http://dx.doi.org/10.1053/j.gastro.2017.04.056">[More Information]</a>

Read, S., O'Connor, K., Suppiah, V., Ahlenstiel, C., Obeid, S., Cook, K., Cunningham, A., Douglas, M., Hogg, P., Booth, D., George, J., Ahlenstiel, G. (2017). Zinc is a potent and specific inhibitor of IFN-(lambda)3 signaling. *Nature Communications*, 8, 1-15. <a href="http://dx.doi.org/10.1038/ncomms15245">[More Information]</a>

## 2016

Zhou, G., Wilson, G., Hebbard, L., Duan, W., Liddle, C., George, J., Qiao, L. (2016). Aptamers: A promising chemical antibody for cancer therapy. *Oncotarget*, 7(12), 13446-13463. <a href="http://dx.doi.org/10.18632/oncotarget.7178">[More Information]</a>

Awan, Z., Tay, E., Eyre, N., Wu, L., Beard, M., Boo, I., Drummer, H., George, J., Douglas, M. (2016). Calsyntenin-1 mediates hepatitis C virus replication. *Journal of General Virology*, 97(8), 1877-1887. <a href="http://dx.doi.org/10.1099/jgv.0.000511">[More Information]</a>

Eslam, M., Mangia, A., Berg, T., Chan, H., Irving, W., Dore, G., Abate, M., Bugianesi, E., Adams, L., Najim, M., Weltman, M., Rahme, A., Booth, D., Liddle, C., Douglas, M., van der Poorten, D., George, J., White, R., Leung, R., et al (2016). Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. *Hepatology*, 64(1), 34-46. <a href="http://dx.doi.org/10.1002/hep.28475">[More Information]</a>

Mahady, S., George, J. (2016). Exercise and diet in the management of nonalcoholic fatty liver disease. *Metabolism: Clinical and Experimental*, 65(8), 1172-1182. <a href="http://dx.doi.org/10.1016/j.metabol.2015.10.032">[More Information]</a>

Eslam, M., Hashem, A., Romero-Gomez, M., Berg, T., Dore, G., Mangia, A., Chan, H., Irving, W., Sheridan, D., Abate, M., Weltman, M., Kelaeng, K., Ahlenstiel, G., Liddle, C., Douglas, M., Booth, D., George, J., et al (2016). FibroGENE: A gene-based model for staging liver fibrosis. *Journal of Hepatology*,

64(2), 390-398. <a href="http://dx.doi.org/10.1016/j.jhep.2015.11.008">[More Information]</a>

Nielsen, M., Karsdal, M., Kazankov, K., Gronbaek, H., Krag, A., Leeming, D., Schuppan, D., George, J. (2016). Fibrosis is not just fibrosis - basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury. *Alimentary Pharmacology and Therapeutics*, 44, 1242-1252. <a href="http://dx.doi.org/10.1111/apt.13819">[More Information]</a>

Eslam, M., George, J. (2016). Genetic and epigenetic mechanisms of NASH. *Hepatology International*, 10(3), 394-406. <a href="http://dx.doi.org/10.1007/s12072-015-9689-y">[More Information]</a>

Heim, M., Bochud, P., George, J. (2016). Host - hepatitis C viral interactions: The role of genetics. *Journal of Hepatology*, 65(1 Suppl), S22-S32. <a href="http://dx.doi.org/10.1016/j.jhep.2016.07.037">[More Information]</a>

O'Connor, K., Read, S., Wang, X., Schibeci, S., Eslam, M., Ong, A., Weltman, M., Douglas, M., Mazzola, A., Craxi, A., Stewart, G., Liddle, C., George, J., Ahlenstiel, G., Booth, D., et al (2016). IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection. *Genes and Immunity*, 17(6), 328-334. <a href="http://dx.doi.org/10.1038/gene.2016.27">[More Information]</a>

Katoonizadeh, A., Sharafkhan, M., Ostovaneh, M., Norouzi, A., Khoshbakht, N., Mohamadkhani, A., Eslami, L., Gharravi, A., Shayanrad, A., Khoshnia, M., Esmaili, S., George, J., et al (2016). Immune responses to hepatitis B immunization 10-18 years after primary vaccination: a population-based cohort study. *Journal of Viral Hepatitis*, 23(10), 805-811. <a href="http://dx.doi.org/10.1111/jvh.12543">[More Information]</a>

Jensen, D., Brunda, M., Elston, R., Gane, E., George, J., Glavini, K., Hammond, J., Le Pogam, S., Najera, I., Passe, S., et al (2016). Interferon-free regimens containing sofosbuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study. *Liver International*, 36(4), 505-514. <a href="http://dx.doi.org/10.1111/liv.12997">[More Information]</a>

Williams, K., Sullivan, D., Veillard, A., O'Brien, R., George, J., Jenkins, A., Young, S., Ehnholm, C., Duffield, A., Twigg, S., Keech, A. (2016). Low alanine aminotransferase levels and higher number of cardiovascular events in people with Type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. *Diabetic Medicine*, 33(3), 356-364. <a href="http://dx.doi.org/10.1111/dme.12972">[More Information]</a>

Sheridan, D., Hajarizadeh, B., Fenwick, F., Matthews, G., Applegate, T., Douglas, M., Neely, D., Askew, B., Dore, G., George, J., et al (2016). Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection. *Liver International*, 36(12), 1774-1782. <a href="http://dx.doi.org/10.1111/liv.13176">[More Information]</a>

Thabet, K., Asimakopoulos, A., Shojaei, M., Romero-Gomez, M., Mangia, A., Irving, W., Berg, T., Dore, G., Gronbaek, H., Sheridan, D., Weltman, M., White, R., Douglas, M., Liddle, C., van der Poorten, D., George, J., Eslam, M., et al (2016). MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. *Nature Communications*, 7, 1-8. <a href="http://dx.doi.org/10.1038/ncomms12757">[More Information]</a>

Information]

Vongsuvan, R., van der Poorten, D., Iseli, T., Strasser, S., McCaughan, G., George, J. (2016). Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma. *PloS One*, 11(5), 1-12. <a href="http://dx.doi.org/10.1371/journal.pone.0155800">[More Information]

Keating, S., Parker, H., Pavey, T., Baker, M., Caterson, I., George, J., Johnson, N. (2016). Objectively Quantified Physical Activity and Sedentary Behavior in Predicting Visceral Adiposity and Liver Fat. *Journal of Obesity*, 2016, 1-10. <a href="http://dx.doi.org/10.1155/2016/2719014">[More Information]

Williams, K., Sullivan, D., Nicholson, G., George, J., Jenkins, A., Januszewski, A., Gebiski, V., Manning, P., Tan, Y., Donoghoe, M., Buizen, L., Twigg, S., Keech, A., et al (2016). Opposite associations between alanine aminotransferase and  $\beta$ -glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. *Metabolism: Clinical and Experimental*, 65(5), 783-793. <a href="http://dx.doi.org/10.1016/j.metabol.2015.12.008">[More Information]

Asimakopoulos, A., Mangia, A., Dore, G., Lloyd, A., George, J., Eslam, M. (2016). Polymorphisms in STAT4 are not associated with treatment response and spontaneous clearance of hepatitis C virus in Europeans. *Hepatology*, 64(6), 2264-2265. <a href="http://dx.doi.org/10.1002/hep.28626">[More Information]

Eslam, M., George, J. (2016). Targeting IFN-lambda: Therapeutic Implications. *Expert Opinion on Therapeutic Targets*, 20(12), 1425-1432. <a href="http://dx.doi.org/10.1080/14728222.2016.1241242">[More Information]

Kazankov, K., Barrera Martinez, F., Moller, H., Rosso, C., Bugianesi, E., David, E., Jouness, R., Esmaili, S., Eslam, M., McLeod, D., George, J., et al (2016). The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. *Liver International*, 36(10), 1549-1557. <a href="http://dx.doi.org/10.1111/liv.13150">[More Information]

Alavi, M., Law, M., Grebely, J., Amin, J., Hajarizadeh, B., George, J., Dore, G. (2016). Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: a population-based study, 1995-2012. *Journal of Hepatology*, 65(5), 879-887. <a href="http://dx.doi.org/10.1016/j.jhep.2016.06.025">[More Information]

Waziry, R., Grebely, J., Amin, J., Alavi, M., Hajarizadeh, B., George, J., Matthews, G., Law, M., Dore, G. (2016). Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014). *Journal of Hepatology*, 65(6), 1086-1093. <a href="http://dx.doi.org/10.1016/j.jhep.2016.08.010">[More Information]

## 2015

Dong, Z., Su, L., Esmaili, S., Iseli, T., Ramezani-Moghadam, M., Hu, L., Xu, A., George, J., Wang, J. (2015). Adiponectin attenuates liver fibrosis by inducing nitric oxide production of hepatic stellate cells. *Journal of Molecular Medicine*, 93(12), 1327-1339. <a href="http://dx.doi.org/10.1007/s00109-015-1313-z">[More Information]

Ramezani-Moghadam, M., Wang, J., Ho, V., Iseli, T.,

Alzahrani, B., Xu, A., van der Poorten, D., Qiao, L., George, J., Hebbard, L. (2015). Adiponectin Reduces Hepatic Stellate Cell Migration by Promoting Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Secretion. *Journal of Biological Chemistry*, 290(9), 5533-5542. <a href="http://dx.doi.org/10.1074/jbc.M114.598011">[More Information]

Williams, K., Burns, K., Constantino, M., Shackel, N., Prakoso, E., Wong, J., Wu, T., George, J., McCaughan, G., Twigg, S. (2015). An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes. *Journal of Diabetes and Its Complications*, 29(8), 1240-1247. <a href="http://dx.doi.org/10.1016/j.jdiacomp.2015.06.015">[More Information]

Dore, G., Lawitz, E., Hezode, C., Shafran, S., Ramji, A., Tatum, H., Taliani, G., Tran, A., Strasser, S., George, J., et al (2015). Daclatasvir plus Peginterferon and Ribavirin is Non-inferior to Peginterferon and Ribavirin Alone, and Reduces Duration of Treatment for HCV Genotype 2 or 3 Infection. *Gastroenterology*, 148(2), 355-366. <a href="http://dx.doi.org/10.1053/j.gastro.2014.10.007">[More Information]

Wilson, G., Hebbard, L., Duan, W., Qiao, L., George, J. (2015). Editorial: Gene therapy for gastrointestinal and liver cancers: past experience, current status and future perspectives. *Current Gene Therapy*, 15(2), 93-96. <a href="http://dx.doi.org/10.2174/156652321502150309094913">[More Information]

Wilson, G., Hebbard, L., Duan, W., George, J., Qiao, L. (2015). Editorial: Induced Pluripotent Stem Cells (iPSCs) in the Gastroenterology and Hepatology: from Basic Research to Clinical Applications. *Current Stem Cell Research & Therapy*, 10(3), 190-192.

Mahady, S., George, J. (2015). Editorial: triglycerides in chronic liver disease - a marker of disease progression? *Alimentary Pharmacology and Therapeutics*, 42(2), 239. <a href="http://dx.doi.org/10.1111/apt.13256">[More Information]

Keating, S., Hackett, D., Parker, H., O'Connor, H., Gerofi, J., Salis (nee Sainsbury), A., Baker, M., Chuter, V., Caterson, I., George, J., Johnson, N. (2015). Effect of aerobic exercise training dose on liver fat and visceral adiposity. *Journal of Hepatology*, 63(1), 174-182. <a href="http://dx.doi.org/10.1016/j.jhep.2015.02.022">[More Information]

Parker, H., O'Connor, H., Cohn, J., Garg, M., Johnson, N., Caterson, I., George, J. (2015). Effect of combined fish oil plus coenzyme Q10 supplementation on Omega-3 Index and cardiovascular risk markers in overweight men. *Joint Annual Scientific Meeting of the Nutrition Society of New Zealand and the Nutrition Society of Australia*, New Zealand: Nutrition Society of Australia and Nutrition Society of New Zealand.

Heeboll, S., Thomsen, K., Clouston, A., Sundelin, E., Radko, Y., Christensen, L., Ramezani-Moghadam, M., Kreutzfeldt, M., Pedersen, S., Jessen, N., Hebbard, L., George, J., et al (2015). Effect of resveratrol on experimental non-alcoholic steatohepatitis. *Pharmacological Research*, 95-96, 34-41. <a href="http://dx.doi.org/10.1016/j.phrs.2015.03.005">[More Information]

Foster, G., Pianko, S., Brown, A., Forton, D., Nahass, R., George, J., Barnes, E., Brainard, D., Massetto, B., Lin, M., et al (2015). Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon-Alfa in Patients with Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients with Cirrhosis

- and Hepatitis C Virus Genotype 2 Infection. *Gastroenterology*, 149(6), 1462-1470. <a href="http://dx.doi.org/10.1053/j.gastro.2015.07.043">[More Information]</a>
- Parker, H., O'Connor, H., Keating, S., Cohn, J., Garg, M., Caterson, I., George, J., Johnson, N. (2015). Efficacy of the Omega-3 Index in predicting non-alcoholic fatty liver disease in overweight and obese adults: a pilot study. *British Journal of Nutrition*, 114(5), 780-787. <a href="http://dx.doi.org/10.1017/S0007114515002305">[More Information]</a>
- Tse, E., Helbig, K., Van der Hoek, K., McCartney, E., Van der Hoek, M., George, J., Beard, M. (2015). Fatty Acids Induce a Pro-Inflammatory Gene Expression Profile in Huh-7 Cells That Attenuates the Anti-HCV Action of Interferon. *Journal of Interferon and Cytokine Research*, 35(5), 392-400. <a href="http://dx.doi.org/10.1089/jir.2014.0165">[More Information]</a>
- Eslam, M., George, J. (2015). Genome-Wide Association Studies and Hepatitis C: Harvesting the Benefits of the Genomic Revolution. *Seminars in Liver Disease*, 35(4), 402-420. <a href="http://dx.doi.org/10.1055/s-0035-1567830">[More Information]</a>
- Read, S., Tay, E., Shahidi, M., O'Connor, K., Booth, D., George, J., Douglas, M. (2015). Hepatitis C Virus Driven AXL Expression Suppresses the Hepatic Type I Interferon Response. *PLoS One*, 10(8), 1-16. <a href="http://dx.doi.org/10.1371/journal.pone.0136227">[More Information]</a>
- Scott, C., Cha, K., Rao, R., Liddle, C., George, J., Gunton, J. (2015). Hepatocyte-Specific Deletion of ARNT (Aryl Hydrocarbon Receptor Nuclear Translocator) Results in Altered Fibrotic Gene Expression in the Thioacetamide Model of Liver Injury. *PLoS One*, 10(3), 1-11. <a href="http://dx.doi.org/10.1371/journal.pone.0121650">[More Information]</a>
- Rueger, S., Bochud, P., Dufour, J., Mullhaupt, B., Semela, D., Helm, M., Moradpour, D., Cerny, A., Malinverni, R., Booth, D., Suppiah, V., George, J., et al (2015). Impact of common risk factors of fibrosis progression in chronic hepatitis C. *Gut*, 64(10), 1605-1615. <a href="http://dx.doi.org/10.1136/gutjnl-2014-306997">[More Information]</a>
- Sublette, V., Hopwood, M., George, J., Smith, S., Perry, K., McCaffery, K., Douglas, M. (2015). Instrumental support to facilitate hepatitis C treatment adherence: Working around shortfalls in shared-care. *Psychology, Health and Medicine*, 20(2), 186-197. <a href="http://dx.doi.org/10.1080/13548506.2014.933852">[More Information]</a>
- Eslam, M., Hashem, A., Leung, R., Romero-Gomez, M., Berg, T., Dore, G., Chan, H., Irving, W., Sheridan, D., Abate, M., Weltman, M., Douglas, M., Liddle, C., Booth, D., George, J., Ahlenstiel, G., et al (2015). Interferon-Î rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. *Nature Communications*, 6, 1-10. <a href="http://dx.doi.org/10.1038/ncomms7422">[More Information]</a>
- Eslam, M., George, J. (2015). Is hepatitis C subtyping still relevant in the era of direct-acting antiviral therapy? *Hepatology International*, 9(1), 5-8. <a href="http://dx.doi.org/10.1007/s12072-014-9600-2">[More Information]</a>
- Buti, M., Fung, S., Gane, E., Afdhal, N., Flisiak, R., Gurel, S., Flaherty, J., Martins, E., Yee, L., Dinh, P., George, J., et al (2015). Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 7½ years. *Hepatology International*, 9(2), 243-250. <a href="http://dx.doi.org/10.1007/s12072-015-9614-4">[More Information]</a>
- Esmaili, S., George, J. (2015). Ltb4r1 inhibitor: A pivotal insulin sensitizer? *Trends in Endocrinology and Metabolism*, 26(5), 221-222. <a href="http://dx.doi.org/10.1016/j.tem.2015.03.007">[More Information]</a>
- Nielsen, M., Kazankov, K., Leeming, D., Karsdal, M., Krag, A., Barrera Martinez, F., McLeod, D., George, J., GrÅ, nbÅk, H. (2015). Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients. *PLoS One*, 10(9), 1-12. <a href="http://dx.doi.org/10.1371/journal.pone.0137302">[More Information]</a>
- Wu, G., Wilson, G., George, J., Qiao, L. (2015). Modulation of Notch Signaling as a Therapeutic Approach for Liver Cancer. *Current Gene Therapy*, 15(2), 171-181. <a href="http://dx.doi.org/10.2174/1566523214666141224100319">[More Information]</a>
- Nguyen, V., George, J. (2015). Nonalcoholic Fatty Liver Disease Management: Dietary and Lifestyle Modifications. *Seminars in Liver Disease*, 35(3), 318-337. <a href="http://dx.doi.org/10.1055/s-0035-1562950">[More Information]</a>
- Wu, G., Wilson, G., Zhou, G., Hebbard, L., George, J., Qiao, L. (2015). Oct4 is a reliable marker of liver tumor propagating cells in hepatocellular carcinoma. *Discovery Medicine*, 20(110), 219-229.
- Petta, S., Vanni, E., Bugianesi, E., Rosso, C., Cabibi, D., Camma, C., Di Marco, F., Eslam, M., Grimaudo, S., Macaluso, F., McLeod, D., George, J., et al (2015). PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. *Alimentary Pharmacology and Therapeutics*, 41(10), 939-948. <a href="http://dx.doi.org/10.1111/apt.13169">[More Information]</a>
- Kazankov, K., Moller, H., Bibby, B., Vilstrup, H., George, J., Gronbaek, H. (2015). Reply. *Hepatology*, 61(2), 735-735. <a href="http://dx.doi.org/10.1002/hep.27302">[More Information]</a>
- Mahady, S., Schlub, T., Bero, L., Moher, D., Tovey, D., George, J., Craig, J. (2015). Side effects are incompletely reported among systematic reviews in gastroenterology. *Journal of Clinical Epidemiology*, 68(2), 144-153. <a href="http://dx.doi.org/10.1016/j.jclinepi.2014.06.016">[More Information]</a>
- Reddy, K., Zeuzem, S., Zoulim, F., Weiland, O., Horban, A., Stanciu, C., Villamil, F., Andreone, P., George, J., Dammers, E., et al (2015). Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. *The Lancet Infectious Diseases*, 15(1), 27-35. <a href="http://dx.doi.org/10.1016/S1473-3099(14)71002-3">[More Information]</a>
- Zhou, G., Wilson, G., George, J., Qiao, L. (2015). Targeting cancer stem cells as a therapeutic approach in liver cancer. *Current Gene Therapy*, 15(2), 161-170. <a href="http://dx.doi.org/10.2174/1566523214666141224095938">[More Information]</a>
- Keating, S., George, J., Johnson, N. (2015). The benefits of exercise for patients with non-alcoholic fatty liver disease. *Expert Review of Gastroenterology and Hepatology*, 9(10),

1247-1250. <a href="http://dx.doi.org/10.1586/17474124.2015.1075392">[More Information]</a>

Bhala, N., George, J. (2015). The Burden of Non-alcoholic Fatty Liver Disease (NAFLD) in the Asia Pacific Region. *Current Hepatology Reports*, 14(2), 77-86. <a href="http://dx.doi.org/10.1007/s11901-015-0264-8">[More Information]</a>

Sublette, V., Smith, S., George, J., McCaffery, K., Douglas, M. (2015). The Hepatitis C treatment experience: Patients' perceptions of the facilitators of and barriers to uptake, adherence and completion. *Psychology & Health*, 30(8), 987-1004. <a href="http://dx.doi.org/10.1080/08870446.2015.1012195">[More Information]</a>

Read, S., Tay, E., Shahidi, M., McLauchlan, J., George, J., Douglas, M. (2015). The Mechanism of Interferon Refractoriness During Hepatitis C Virus Infection and Its Reversal with a Peroxisome Proliferator-Activated Receptor [alpha] Agonist. *Journal of Interferon and Cytokine Research*, 35(6), 486-497. <a href="http://dx.doi.org/10.1089/jir.2014.0209">[More Information]</a>

Duong, H., Dong, Z., Su, L., Boyer, C., George, J., Davis, T., Wang, J. (2015). The Use of Nanoparticles to Deliver Nitric Oxide to Hepatic Stellate Cells for Treating Liver Fibrosis and Portal Hypertension. *Small*, 11(19), 2291-2304. <a href="http://dx.doi.org/10.1002/smll.201402870">[More Information]</a>

## 2014

Douglas, M., Esmaili, S., George, J. (2014). A new role for IKK-alpha in Hepatitis C virus induced lipogenesis. *Hepatology*, 59(5), 2046-2049. <a href="http://dx.doi.org/10.1002/hep.26887">[More Information]</a>

Muir, A., Arora, S., Everson, G., Flisiak, R., George, J., Ghalib, R., Gordon, S., Gray, T., Greenbloom, S., Hassanein, T., et al (2014). A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. *Journal of Hepatology*, 61(6), 1238-1246. <a href="http://dx.doi.org/10.1016/j.jhep.2014.07.022">[More Information]</a>

Beard, M., Ffrench, R., Gowans, E., Helbig, K., Eyre, N., Douglas, M., Grebely, J., Ahlenstiel, G., Locarnini, S., George, J., et al (2014). A Summary of the 20(th) International Symposium on Hepatitis C Virus and Related Viruses. *Gastroenterology*, 147(1), e1-e4. <a href="http://dx.doi.org/10.1053/j.gastro.2014.05.022">[More Information]</a>

Musso, G., Gambino, R., Tabibian, J., Ekstedt, M., Kechagias, S., Hamaguchi, M., Hultcrantz, R., Hagstrom, H., Yoon, S., Charatcharoenwitthaya, P., George, J., Barrera Martinez, F., et al (2014). Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. *PLoS Medicine*, 11(7), 1-26. <a href="http://dx.doi.org/10.1371/journal.pmed.1001680">[More Information]</a>

Poustchi, H., Katoonizadeh, A., Ostovaneh, M., Moossavi, S., Sharafkhah, M., Esmaili, S., Pourshams, A., Mohamadkhani, A., Besharat, S., Merat, S., George, J., et al (2014). Cohort profile: Golestan Hepatitis B Cohort Study- A Prospective Long Term Study in Northern Iran. *Middle East Journal of Digestive Diseases*, 6(4), 186-194.

Robotin, M., George, J. (2014). Community-based hepatitis B

screening: what works? *Hepatology International*, 8(4), 478-492. <a href="http://dx.doi.org/10.1007/s12072-014-9562-4">[More Information]</a>

Robotin, M., Kansil, M., Porwal, M., Penman, A., George, J. (2014). Community-based prevention of hepatitis-B-related liver cancer: Australian insights. *Bulletin of the World Health Organization*, 92(5), 374-379. <a href="http://dx.doi.org/10.2471/BLT.13.130344">[More Information]</a>

O'Connor, K., George, J., Booth, D., Ahlenstiel, G. (2014). Dendritic cells in hepatitis C virus infection: Key players in the IFNL3-genotype response. *World Journal of Gastroenterology*, 20(47), 17830-17838. <a href="http://dx.doi.org/10.3748/wjg.v20.i47.17830">[More Information]</a>

Flynn, J., Sacks-Davis, R., Higgs, P., Aitken, C., Moneer, S., Suppiah, V., Tracy, L., Ffrench, R., Bowden, S., Drummer, H., George, J., et al (2014). Detection of HCV-Specific IFN-gamma Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users. *Hepatitis Monthly*, 14(1), 1-14. <a href="http://dx.doi.org/10.5812/hepatmon.14678">[More Information]</a>

Roberts, S., Mitchell, J., Leung, R., Booth, D., Bollipo, S., Ostapowicz, G., Sloss, A., McCaughan, G., Dore, G., Thompson, A., George, J., et al (2014). Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies. *Journal of Gastroenterology and Hepatology*, 29(1), 179-184. <a href="http://dx.doi.org/10.1111/jgh.12424">[More Information]</a>

Heeboll, S., Thomsen, K., Pedersen, S., Vilstrup, H., George, J., Gronbaek, H. (2014). Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. *World Journal of Hepatology*, 6(4), 188-198. <a href="http://dx.doi.org/10.4254/wjh.v6.i4.188">[More Information]</a>

Parker, H., O'Connor, H., Keating, S., Cohn, J., Garg, M., Caterson, I., George, J., Johnson, N. (2014). Efficacy of the Omega-3 Index in predicting NAFLD in overweight and obese adults: a pilot study. *2014 Australian and New Zealand Obesity Society Annual Scientific Meeting*, Sydney, Australia: Australian and New Zealand Obesity Society.

Shahidi, M., Tay, E., Read, S., Ramezani-Moghadam, M., Chayama, K., George, J., Douglas, M. (2014). Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host-targeting agents. *Journal of General Virology*, 95(11), 2468-2479. <a href="http://dx.doi.org/10.1099/vir.0.067231-0">[More Information]</a>

Milner, K., Jenkins, A., Trenell, M., Tid-Ang, J., Samocho-Bonet, D., Weltman, M., Xu, A., George, J., Chisholm, D. (2014). Eradicating hepatitis C virus ameliorates insulin resistance without change in adipose depots. *Journal of Viral Hepatitis*, 21(5), 325-332. <a href="http://dx.doi.org/10.1111/jvh.12143">[More Information]</a>

Thomsen, K., Gronbaek, H., Glavind, E., Hebbard, L., Jessen, N., Clouston, A., George, J., Vilstrup, H. (2014). Experimental nonalcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function. *American Journal of Physiology: Gastrointestinal and Liver Physiology*, 307(3), G295-G301. <a href="http://dx.doi.org/10.1152/ajpgi.00036.2014">[More Information]</a>



O'Connor, K., Parnell, G., Patrick, E., Ahlenstiel, G., Suppiah, V., van der Poorten, D., Read, S., Leung, R., Douglas, M., Yang, J., Stewart, G., Liddle, C., George, J., Booth, D. (2014). Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent. *Genes and Immunity*, 15(2), 88-94. <a href="http://dx.doi.org/10.1038/gene.2013.66">[More Information]</a>

Read, S., Tay, E., Shahidi, M., George, J., Douglas, M. (2014). Hepatitis C virus infection mediates cholesteryl ester synthesis to facilitate infectious particle production. *Journal of General Virology*, 95(9), 1900-1910. <a href="http://dx.doi.org/10.1099/vir.0.065300-0">[More Information]</a>

O'Connor, K., Ahlenstiel, G., Suppiah, V., Schibeci, S., Ong, A., Leung, R., van der Poorten, D., Douglas, M., Weltman, M., Stewart, G., Liddle, C., George, J., Booth, D. (2014). IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis. *Innate Immunity*, 20(6), 598-605. <a href="http://dx.doi.org/10.1177/1753425913503385">[More Information]</a>

Eslam, M., Leung, R., Romero-Gomez, M., Mangia, A., Irving, W., Sheridan, D., Spengler, U., Mollison, L., Cheng, W., Bugianesi, E., Douglas, M., Booth, D., George, J., Ahlenstiel, G., et al (2014). IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. *Journal of Hepatology*, 61(2), 235-241. <a href="http://dx.doi.org/10.1016/j.jhep.2014.03.039">[More Information]</a>

Kitson, M., George, J., Dore, G., Leung, R., Button, P., McCaughan, G., Crawford, D., Sievert, W., Weltman, M., Cheng, W., et al (2014). Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection. *Journal of Gastroenterology and Hepatology*, 29, 1458-1462. <a href="http://dx.doi.org/10.1111/jgh.12544">[More Information]</a>

Thomsen, K., Hebbard, L., Glavind, E., Clouston, A., Vilstrup, H., George, J., GrÅ, nbÅ, k, H. (2014). Non-alcoholic steatohepatitis weakens the acute phase response to endotoxin in rats. *Liver International*, 34(10), 1584-1592. <a href="http://dx.doi.org/10.1111/liv.12547">[More Information]</a>

Parker, H., O'Connor, H., Keating, S., Cohn, J., Garg, M., Caterson, I., George, J., Johnson, N. (2014). Omega-3 Index and liver fat: an unexpected relationship. *Nutrition Society of Australia 2014 Annual Scientific Meeting*, Australia.

Wilson, G., George, J. (2014). Physical and Chemical Insults Induce Inflammation and Gastrointestinal Cancers. *Cancer Letters*, 345(2), 190-195. <a href="http://dx.doi.org/10.1016/j.canlet.2013.07.011">[More Information]</a>

Barrera, F., George, J. (2014). Prothrombotic Factors and Nonalcoholic Fatty Liver Disease: An Additional Link to Cardiovascular Risk? *Hepatology*, 59(1), 16-18. <a href="http://dx.doi.org/10.1002/hep.26588">[More Information]</a>

Angulo, P., George, J., Day, C., Vanni, E., Russell, L., De la Cruz, A., Liaquat, H., Mezzabotta, L., Lee, E., Bugianesi, E. (2014). Serum Ferritin Levels Lack Diagnostic Accuracy for Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. *Clinical Gastroenterology and Hepatology*, 12(7), 1163-1169. <a href="http://dx.doi.org/10.1016/j.cgh.2013.11.035">[More Information]</a>

<a href="http://dx.doi.org/10.1016/j.cgh.2013.11.035">[More Information]</a>

Dai, Y., Wilson, G., Huang, B., Peng, M., Teng, G., Zhang, D., Zhang, R., Ebert, M., Chen, J., Wong, B., George, J., Qiao, L., et al (2014). Silencing of Jagged1 inhibits cell growth and invasion in colorectal cancer. *Cell Death and Disease*, 5, 1-9. <a href="http://dx.doi.org/10.1038/cddis.2014.137">[More Information]</a>

Kazankov, K., Barrera Martinez, F., MÅ, ller, H., Bibby, B., Vilstrup, H., George, J., GrÅ, nbÅ, k, H. (2014). Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. *Hepatology*, 60(2), 521-530. <a href="http://dx.doi.org/10.1002/hep.27129">[More Information]</a>

Tian, A., Wilson, G., Lie, S., Wu, G., Hu, Z., Hebbard, L., Duan, W., George, J., Qiao, L. (2014). Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells. *Cancer Letters*, 351(2), 232-241. <a href="http://dx.doi.org/10.1016/j.canlet.2014.06.006">[More Information]</a>

Grebely, J., Page, K., Sacks-Davis, R., Schim van der Loeff, M., Rice, T., Bruneau, J., Morris, M., Hajarizadeh, B., Amin, J., Cox, A., George, J., et al (2014). The Effects of Female Sex, Viral Genotype, and IL28B Genotype on Spontaneous Clearance of Acute Hepatitis C Virus Infection. *Hepatology*, 59(1), 109-120. <a href="http://dx.doi.org/10.1002/hep.26639">[More Information]</a>

Saeed, E., Xu, A., George, J. (2014). The multifaceted and controversial immunometabolic actions of adiponectin. *Trends in Endocrinology and Metabolism*, 25(9), 444-451. <a href="http://dx.doi.org/10.1016/j.tem.2014.06.001">[More Information]</a>

Barrera Martinez, F., George, J. (2014). The Role of Diet and Nutritional Intervention for the Management of Patients with NAFLD. *Clinics in Liver Disease*, 18(1), 91-112. <a href="http://dx.doi.org/10.1016/j.cld.2013.09.009">[More Information]</a>

## 2013

Fischer, J., Bohm, S., Muller, T., Witt, H., Sarrazin, C., Susser, S., Migaud, P., Schott, E., Stewart, G., Brodzinski, A., George, J., et al (2013). Association of IFNL3 rs12979860 and rs8099917 with Biochemical Predictors of Interferon Responsiveness in Chronic Hepatitis C Virus Infection. *PLoS One*, 8(10), 1-11. <a href="http://dx.doi.org/10.1371/journal.pone.0077530">[More Information]</a>

Fahrtash, F., Kariyawasam, V., Gray, T., Byth Wilson, K., George, J., Douglas, M. (2013). Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B. *World Journal of Gastroenterology*, 19(5), 721-726. <a href="http://dx.doi.org/10.3748/wjg.v19.i5.721">[More Information]</a>

Suppiah, V., Armstrong, N., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Dore, G., Irving, W., Stewart, G., George, J., Booth, D., Ahlenstiel, G., et al (2013). CCR5-Delta32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. *Genes and Immunity*, 14(5), 286-290. <a href="http://dx.doi.org/10.1038/gene.2013.15">[More Information]</a>

Carulli, L., Maurantonio, M., Hebbard, L., Baldelli, E., Loria,

- P., George, J. (2013). Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD. *Current Pharmaceutical Design*, 19(29), 5280-5296. <a href="http://dx.doi.org/10.2174/1381612811319290009">[More Information]</a>
- Kim, M., Lee, K., Iseli, T., Hoy, A., George, J., Grewal, T., Roufogalis, B. (2013). Compound K modulates fatty acid-induced lipid droplet formation and expression of proteins involved in lipid metabolism in hepatocytes. *Liver International*, 33(10), 1583-1593. <a href="http://dx.doi.org/10.1111/liv.12287">[More Information]</a>
- Hu, L., George, J., Wang, J. (2013). Current concepts on the role of nitric oxide in portal hypertension. *World Journal of Gastroenterology*, 19(11), 1707-1717. <a href="http://dx.doi.org/10.3748/wjg.v19.i11.1707">[More Information]</a>
- Foster, G., Zeuzem, S., Pianko, S., Sarin, S., Piratvisuth, T., Shah, S., Andreone, P., Sood, A., Chuang, W., Lee, C., George, J., et al (2013). Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin. *Journal of Viral Hepatitis*, 20(4), e115-e123. <a href="http://dx.doi.org/10.1111/jvh.12020">[More Information]</a>
- Petta, S., Rosso, C., Leung, R., Abate, M., Booth, D., Solomone, F., Gambino, R., Rizzetto, M., Caviglia, P., Smedile, A., George, J., et al (2013). Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients with Genotype 1 Chronic Hepatitis C. *Clinical Gastroenterology and Hepatology*, 11(3), 311-317. <a href="http://dx.doi.org/10.1016/j.cgh.2012.11.022">[More Information]</a>
- Wilson, G., Hu, Z., Duan, W., Tian, A., Wang, X., McCleod, D., Lam, V., George, J., Qiao, L. (2013). Efficacy of Using Cancer Stem Cell Markers in Isolating and Characterising Liver Cancer Stem Cells. *Stem Cells and Development*, 22(19), 2655-2664. <a href="http://dx.doi.org/10.1089/scd.2012.0703">[More Information]</a>
- Robotin, M., Patton, Y., George, J. (2013). Getting it right: The impact of a continuing medical education program on hepatitis B knowledge of Australian primary care providers. *International Journal of General Medicine*, 6, 115-122. <a href="http://dx.doi.org/10.2147/IJGM.S41299">[More Information]</a>
- van der Poorten, D., Samer, C., Ramezani-Moghadam, M., Coulter, S., Kacevska, M., Schrijnders, D., Wu, L., McLeod, D., Bugianesi, E., Komuta, M., Liddle, C., Hebbard, L., George, J., et al (2013). Hepatic Fat Loss in Advanced Nonalcoholic Steatohepatitis: Are Alterations in Serum Adiponectin the Cause? *Hepatology*, 57(6), 2180-2188. <a href="http://dx.doi.org/10.1002/hep.26072">[More Information]</a>
- Sacks-Davis, R., Atiken, C., Higgs, P., Spelman, T., Pedrana, A., Bowden, S., Bharadwaj, M., Nivarthi, U., Suppiah, V., George, J., et al (2013). High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: A prospective cohort study. *PLoS One*, 8(11), 1-12. <a href="http://dx.doi.org/10.1371/journal.pone.0080216">[More Information]</a>
- Gelinas, J., Fabre, T., Willems, P., Leung, R., George, J., Willems, B., Bruneau, J., Shoukry, N. (2013). IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based test. *Immunogenetics*, 65(6), 397-403. <a href="http://dx.doi.org/10.1007/s00251-013-0688-7">[More Information]</a>
- Fischer, J., Bohm, S., George, J., Sarrazin, C., Berg, T. (2013). Impact of cohort size and host factors on combined analysis of interleukin 28B rs12979860 and rs8099917 in hepatitis C virus infection. *Hepatology*, 57(1), 416-417. <a href="http://dx.doi.org/10.1002/hep.25923">[More Information]</a>
- Eslam, M., Booth, D., George, J., Ahlenstiel, G. (2013). Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection. *World Journal of Gastroenterology*, 19(41), 7055-7061. <a href="http://dx.doi.org/10.3748/wjg.v19.i41.7055">[More Information]</a>
- Booth, D., George, J. (2013). Loss of function of the new interferon IFN- $\lambda$ 4 may confer protection from hepatitis C. *Nature Genetics*, 45(2), 119-120. <a href="http://dx.doi.org/10.1038/ng.2537">[More Information]</a>
- Barrera Martinez, F., George, J. (2013). Non-alcoholic fatty liver disease: more than just ectopic fat accumulation. *Drug Discovery Today: Disease Mechanisms*, 10(1-2), e47-e54. <a href="http://dx.doi.org/10.1016/j.ddmec.2013.06.002">[More Information]</a>
- Hashemi, S., van der Poorten, D., Barrera Martinez, F., Bandara, P., Lux, O., Kench, J., George, J. (2013). Oxidative stress is closely associated with insulin resistance in genotypes 1 and 3 chronic hepatitis C. *Hepatology International*, 7(2), 516-523. <a href="http://dx.doi.org/10.1007/s12072-012-9400-5">[More Information]</a>
- Grebely, J., Feld, J., Applegate, T., Matthews, G., Hellard, M., Sherker, A., Petoumenos, K., Zang, G., Shaw, I., Yeung, B., George, J., et al (2013). Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. *Hepatology*, 57(6), 2124-2134. <a href="http://dx.doi.org/10.1002/hep.26263">[More Information]</a>
- Sublette, V., Douglas, M., McCaffery, K., George, J., Nicholson Perry, K. (2013). Psychological, lifestyle and social predictors of hepatitis C treatment response: a systematic review. *Liver International*, 33(6), 894-903. <a href="http://dx.doi.org/10.1111/liv.12138">[More Information]</a>
- Dong, Z., Su, L., Brymora, J., Bird, C., Xie, Q., George, J., Wang, J. (2013). Resistin mediates the hepatic stellate cell phenotype. *World Journal of Gastroenterology*, 19(28), 4475-4485. <a href="http://dx.doi.org/10.3748/wjg.v19.i28.4475">[More Information]</a>
- Angulo, P., Bugianesi, E., Bjornsson, E., Charatcharoenwitthaya, P., Mills, P., Barrera Martinez, F., Hafliadottir, S., Day, C., George, J. (2013). Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. *Gastroenterology*, 145(4), 782-789. <a href="http://dx.doi.org/10.1053/j.gastro.2013.06.057">[More Information]</a>
- Mahady, S., George, J. (2013). The Future Liver of the Asia Pacific: Fatter and Firmer from More Fructose and Fortune? *Journal of Clinical and Experimental Hepatology*, 3(2), 106-113. <a href="http://dx.doi.org/10.1016/j.jceh.2012.10.011">[More Information]</a>
- Poustchi, H., Eslami, M., Ostovaneh, M., Modabbernia, A., Saeedian, F., Taslimi, S., George, J., Malekzadeh, R., Zamani, F. (2013). Transient elastography in hepatitis C virus-infected

patients with beta-thalassemia for assessment of fibrosis. *Hepatology Research*, 43(12), 1276-1283. <a href="http://dx.doi.org/10.1111/hepr.12088">[More Information]</a>

Wilson, G., Tian, A., Hebbard, L., Duan, W., George, J., Li, X., Qiao, L. (2013). Tumorcidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro. *Cancer Letters*, 341(2), 224-230. <a href="http://dx.doi.org/10.1016/j.canlet.2013.08.009">[More Information]</a>

Vongsuvan, R., George, J., Qiao, L., van der Poorten, D. (2013). Visceral adiposity in gastrointestinal and hepatic carcinogenesis. *Cancer Letters*, 330(1), 1-10. <a href="http://dx.doi.org/10.1016/j.canlet.2012.11.038">[More Information]</a>

Kitson, M., Dore, G., George, J., Button, P., McCaughan, G., Crawford, D., Sievert, W., Weltman, M., Cheng, W., Roberts, S. (2013). Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. *Journal of Hepatology*, 58(3), 467-472. <a href="http://dx.doi.org/10.1016/j.jhep.2012.11.017">[More Information]</a>

## 2012

Nguyen, V., George, J., van der Poorten, D. (2012). A maxillary mass in a HBV-cirrhotic patient. *Liver International*, 32(6), 988-988. <a href="http://dx.doi.org/10.1111/j.1478-3231.2012.02780.x">[More Information]</a>

Rahman, W., Huang, P., Belov, L., Chrisp, J., Christopherson, R., Stapelberg, P., Warner, F., George, J., Bowen, D., Strasser, S., Koorey, D., Sharland, A., McCaughan, G., Shackel, N. (2012). Analysis of human liver disease using a cluster of differentiation (CD) antibody microarray. *Liver International*, 32(10), 1527-1534. <a href="http://dx.doi.org/10.1111/j.1478-3231.2012.02854.x">[More Information]</a>

Walker, S., George, J., Hebbard, L. (2012). Animal Models of Hepatocellular Carcinoma. In Liang Qiao, Yumin Li, Xiang Yan and Jacob George (Eds.), *Molecular Aspects of Hepatocellular Carcinoma*, (pp. 116-128). Sharjah: Bentham Science Publishers. <a href="http://dx.doi.org/10.2174/978160805072711201010116">[More Information]</a>

Parker, H., Keating, S., O'Connor, H., Cohn, J., Caterson, I., George, J., Johnson, N. (2012). Can reported short-term dietary intake predict fatty liver? *Nutrition Society of Australia 2012 Annual Scientific Meeting*, Not-Known.

Fischer, J., Bohm, S., Scholz, M., Muller, T., Witt, H., George, J., Sarrazin, C., Susser, S., Schott, E., Suppiah, V., Booth, D., Stewart, G., et al (2012). Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. *Hepatology*, 55(6), 1700-1710. <a href="http://dx.doi.org/10.1002/hep.25582">[More Information]</a>

Raftopoulos, S., George, J., Bourliere, M., Rossi, E., de Boer, W., Jeffrey, G., Bulsara, M., Speers, D., MacQuillan, G., Ching, H., McLeod, D., et al (2012). Comparison of noninvasive models of fibrosis in chronic hepatitis B. *Hepatology International*, 6(2), 457-467. <a href="http://dx.doi.org/10.1007/s12072-011-9296-5">[More Information]</a>

Robotin, M., Patton, Y., Kansil, M., Penman, A., George, J. (2012). Cost of treating chronic hepatitis B: Comparison of current treatment guidelines. *World Journal of Gastroenterology*, 18(42), 6106-6113. <a href="http://dx.doi.org/10.3748/wjg.v18.i42.6106">[More Information]</a>

Johnson, N., van Overbeek, D., Chapman, P., Thompson, M., Sachinwalla, T., George, J. (2012). Effect of prolonged exercise and pre-exercise dietary manipulation on hepatic triglycerides in trained men. *European Journal of Applied Physiology*, 112(5), 1817-1825. <a href="http://dx.doi.org/10.1007/s00421-011-2158-y">[More Information]</a>

Keating, S., Hackett, D., George, J., Johnson, N. (2012). Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis. *Journal of Hepatology*, 57(1), 157-166. <a href="http://dx.doi.org/10.1016/j.jhep.2012.02.023">[More Information]</a>

Johnson, N., Keating, S., George, J. (2012). Exercise and the Liver: Implications for Therapy in Fatty Liver Disorders. *Seminars in Liver Disease*, 32(1), 65-79. <a href="http://dx.doi.org/10.1055/s-0032-1306427">[More Information]</a>

Patin, E., Kutalik, Z., Guernon, J., Bibert, S., Nalpas, B., Jouanguy, E., Munteanu, M., Bousquet, L., Argiro, L., Halfon, P., Suppiah, V., Stewart, G., Booth, D., George, J., et al (2012). Genome-Wide Association Study Identifies Variants Associated With Progression of Liver Fibrosis From HCV Infection. *Gastroenterology*, 143(5), 1244-1252. <a href="http://dx.doi.org/10.1053/j.gastro.2012.07.097">[More Information]</a>

Gidding, H., Law, M., Amin, J., Ostapowicz, G., Weltman, M., Macdonald, G., Sasadeusz, J., Haber, P., George, J., Dore, G. (2012). Hepatitis C treatment outcomes in Australian clinics. *Medical Journal of Australia*, 196(10), 633-637. <a href="http://dx.doi.org/10.5694/mja12.10014">[More Information]</a>

Mahady, S., George, J. (2012). Management of nonalcoholic steatohepatitis: an evidence-based approach. *Clinics in Liver Disease*, 16(3), 631-645. <a href="http://dx.doi.org/10.1016/j.cld.2012.05.003">[More Information]</a>

Qiao, L., Li, Y., Yan, X., George, J. (2012). *Molecular Aspects of Hepatocellular Carcinoma*. Sharjah: Bentham Science Publishers.

Parker, H., Johnson, N., Burdon, C., Cohn, J., O'Connor, H., George, J. (2012). Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis. *Journal of Hepatology*, 56(4), 944-951. <a href="http://dx.doi.org/10.1016/j.jhep.2011.08.018">[More Information]</a>

Booth, D., Ahlenstiel, G., George, J. (2012). Pharmacogenomics of hepatitis C infections: personalizing therapy. *Genome Medicine*, 4(12), 1-10. <a href="http://dx.doi.org/10.1186/gm400">[More Information]</a>

Mahady, S., Wong, G., Craig, J., George, J. (2012). Pioglitazone and Vitamin E for Nonalcoholic Steatohepatitis: A Cost Utility Analysis. *Hepatology*, 56(6), 2172-2179. <a href="http://dx.doi.org/10.1002/hep.25887">[More Information]</a>

Pianko, S., Zeuzem, S., Chuang, W., Foster, G., Sarin, S., Flisiak, R., Lee, C., Andreone, P., Piratvisuth, T., Shah, S., George, J., et al (2012). Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. *Journal of Viral Hepatitis*, 19(9), 623-634. <a href="http://dx.doi.org/10.1111/j.1365-2893.2012.01586.x">[More Information]</a>

Pianko, S., Zeuzem, S., Chuang, W., Foster, G., Sarin, S., Flisiak, R., Lee, C., Andreone, P., Piratvisuth, T., Shah, S., George, J., et al (2012). Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. *Journal of Viral Hepatitis*, 19(9), 623-634. <a href="http://dx.doi.org/10.1111/j.1365-2893.2012.01586.x">[More Information]</a>

Poustchi, H., George, J. (2012). Reply. *Hepatology*, 55(6), 2039-2040. <a href="http://dx.doi.org/10.1002/hep.25586">[More Information]</a>

Parker, H., Johnson, N., George, J. (2012). Reply to: "The optimal dose of omega-3 supplementation for non-alcoholic fatty liver disease". *Journal of Hepatology*, 57(2), 469-470. <a href="http://dx.doi.org/10.1016/j.jhep.2012.02.032">[More Information]</a>

Thein, H., Walter, S., Gidding, H., Amin, J., Law, M., George, J., Dore, G. (2012). Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort. *Hepatology Research*, 42(12), 1175-1186. <a href="http://dx.doi.org/10.1111/j.1872-034X.2012.01037.x">[More Information]</a>

Pattullo, V., George, J. (2012). The Problem of Insulin Resistance and its Effect on Therapy. In Geoffrey W. McCaughan, John G. McHutchison, Jean-Michel Pawlotsky (Eds.), *Advanced Therapy for Hepatitis C*, (pp. 169-176). Chichester, United Kingdom: Wiley-Blackwell Publishing. <a href="http://dx.doi.org/10.1002/9781444346343.ch21">[More Information]</a>

Grebely, J., Hellard, M., Applegate, T., Petoumenos, K., Yeung, B., Feld, J., Rawlinson, W., Lloyd, A., George, J., Kaldor, J., et al (2012). Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection. *AIDS*, 26(13), 1653-1661. <a href="http://dx.doi.org/10.1097/QAD.0b013e3283553719">[More Information]</a>

Vongsuvan, R., George, J., McLeod, D., van der Poorten, D. (2012). Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease. *Journal of Hepatology*, 57(2), 392-398. <a href="http://dx.doi.org/10.1016/j.jhep.2012.03.013">[More Information]</a>

Ahlenstiel, G., Booth, D., George, J. (2012). Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms? *Antiviral Therapy*, 17(6 Pt B), 1163-1170. <a href="http://dx.doi.org/10.3851/IMP2427">[More Information]</a>

## 2011

Hebbard, L., George, J. (2011). Animal models of nonalcoholic fatty liver disease. *Nature Reviews. Gastroenterology & Hepatology*, 8(1), 35-44. <a href="http://dx.doi.org/10.1038/nrgastro.2010.191">[More Information]</a>

Ahlenstiel, G., Booth, D., George, J. (2011). Clinical significance of IL28B gene variation in hepatitis C virus infection. *Hot Topics in viral Hepatitis*, (20), 17-24. <a href="http://dx.doi.org/10.4147/HTV-112017">[More Information]</a>

Adams, L., George, J., Bugianesi, E., Rossi, E., de Boer, W., van der Poorten, D., Ching, H., Bulsara, M., Jeffrey, G. (2011). Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. *Journal of Gastroenterology and Hepatology*, 26(10), 1536-1543. <a href="http://dx.doi.org/10.1111/j.1440-1746.2011.06774.x">[More Information]</a>

Poustchi, H., Farrell, G., Strasser, S., Lee, A., McCaughan, G., George, J. (2011). Feasibility of conducting a randomised control trial for liver cancer screening: Is a randomized controlled trial for liver cancer screening feasible or still needed? *Hepatology*, 54(6), 1998-2004. <a href="http://dx.doi.org/10.1002/hep.24581">[More Information]</a>

Poustchi, H., George, J., Esmaili, S., Esna-Ashari, F., Ardalan, G., Sepanlou, G., Alavian, S. (2011). Gender differences in healthy ranges for serum alanine aminotransferase levels in adolescence. *PLoS One*, 6(6), e21178-1-e21178-7. <a href="http://dx.doi.org/10.1371/journal.pone.0021178">[More Information]</a>

Smith, K., Suppiah, V., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Matthews, G., Irving, W., Ahlenstiel, G., Stewart, G., George, J., Booth, D., et al (2011). Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. *Genome Medicine*, 3(8), 57-1-57-13. <a href="http://dx.doi.org/10.1186/gm273">[More Information]</a>

Suppiah, V., Gaudieri, S., Armstrong, N., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Dore, G., Ahlenstiel, G., Stewart, G., George, J., Booth, D., et al (2011). IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study. *PLoS Medicine*, 8(9), e1001092-1-e1001092-8. <a href="http://dx.doi.org/10.1371/journal.pmed.1001092">[More Information]</a>

Liu, Y., Brymora, J., Zhang, H., Smith, B., Ramezani-Moghadam, M., George, J., Wang, J. (2011). Leptin and Acetaldehyde Synergistically Promotes aSMA Expression in Hepatic Stellate Cells by an Interleukin 6-Dependent Mechanism. *Alcoholism: Clinical and Experimental Research*, 35(5), 921-928. <a href="http://dx.doi.org/10.1111/j.1530-0277.2010.01422.x">[More Information]</a>

Park, G., Wiseman, E., George, J., Katelaris, P., Seow, F., Fung, C., Ngu, M. (2011). Non-invasive Estimation of Liver Fibrosis in Non-alcoholic Fatty Liver Disease Using the (13) C-Caffeine Breath Test. *Journal of Gastroenterology and Hepatology*, 26(9), 1411-1416. <a href="http://dx.doi.org/10.1111/j.1440-1746.2011.06760.x">[More Information]</a>

Parker, H., Burdon, C., O'Connor, H., George, J., Cohn, J., Johnson, N. (2011). Omega-3 fatty acid supplementation for non-alcoholic fatty liver disease in humans: a systematic review and meta-analysis. *International Conference on the Science of Nutrition in Medicine and Healthcare 2011*, Sydney, Australia: The Science of Nutrition in Medicine and Healthcare.

Patel, K., Jhaveri, R., George, J., Qiang, G., Kenedi, C., Brown, K., Cates, C., Zekry, A., Tillmann, H., Elliott, L., et al (2011). Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C. *Journal of Viral Hepatitis*, 18(5), 331-337. <a href="http://dx.doi.org/10.1111/j.1365-2893.2010.01310.x">[More Information]</a>

Pattullo, V., Douglas, M., George, J. (2011). Organelle dysfunction in hepatitis C virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis? *Expert Review of Gastroenterology and Hepatology*, 5(2), 265-277. <a href="http://dx.doi.org/10.1586/EGH.11.12">[More Information]</a>

Gidding, H., Law, M., Amin, J., Macdonald, G., Sasadeusz, J., Jones, T., Strasser, S., George, J., Dore, G. (2011). Predictors of deferral of treatment for hepatitis C infection in Australian clinics. *Medical Journal of Australia*, 194(8), 398-402. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list\_uids=21495939">[More Information]</a>

Walter, S., Thein, H., Gidding, H., Amin, J., Law, M., George,

J., Dore, G. (2011). Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. *Journal of Gastroenterology and Hepatology*, 26(12), 1757-1764. <a href="http://dx.doi.org/10.1111/j.1440-1746.2011.06785.x">[More Information]</a>

Jacobson, I., McHutchison, J., Dusheiko, G., Di Bisceglie, A., Reddy, K., Bzowej, N., Marcellin, P., Muir, A., Ferenci, P., Flisiak, R., George, J., et al (2011). Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection. *New England Journal of Medicine*, 364(25), 2405-2416. <a href="http://dx.doi.org/10.1056/NEJMoa1012912">[More Information]</a>

Bhala, N., Angulo, P., van der Poorten, D., Lee, E., Hui, J., Saracco, G., Adams, L., Charatcharoenwitthaya, P., Topping, J., Bugianesi, E., George, J., et al (2011). The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study. *Hepatology*, 54(4), 1208-1216. <a href="http://dx.doi.org/10.1002/hep.24491">[More Information]</a>

Mahady, S., Webster, A., Walker, S., Sanyal, A., George, J. (2011). The role of thiazolidinediones in non-alcoholic steatohepatitis - A systematic review and meta analysis. *Journal of Hepatology*, 55(6), 1383-1390. <a href="http://dx.doi.org/10.1016/j.jhep.2011.03.016">[More Information]</a>

Thein, H., Walter, S., Gidding, H., Amin, J., Law, M., George, J., Dore, G. (2011). Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a population-based cohort study, 1992-2007. *Journal of Viral Hepatitis*, 18(7), e232-e241. <a href="http://dx.doi.org/10.1111/j.1365-2893.2011.01440.x">[More Information]</a>

Walter, S., Thein, H., Amin, J., Gidding, H., Ward, K., Law, M., George, J., Dore, G. (2011). Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. *Journal of Hepatology*, 54(5), 879-886. <a href="http://dx.doi.org/10.1016/j.jhep.2010.08.035">[More Information]</a>

## 2010

Johnson, N., George, J. (2010). An Active Part in Treating Liver Disease. Exercise In Medical Conditions: Exercise And Non-Alcoholic Fatty Liver Disease. *SportEx Health*, 25, 18-20.

Milner, K., van der Poorten, D., Trenell, M., Jenkins, A., Xu, A., Smythe, G., Dore, G., Zekry, A., Weltman, M., Fragomeli, V., George, J., et al (2010). Chronic Hepatitis C is Associated with Peripheral rather than Hepatic Insulin Resistance. *Gastroenterology*, 138(3), 932-941. <a href="http://dx.doi.org/10.1053/j.gastro.2009.11.050">[More Information]</a>

Johnson, N., George, J. (2010). Fitness Versus Fatness: Moving Beyond Weight Loss in Nonalcoholic Fatty Liver Disease. *Hepatology*, 52(1), 370-381. <a href="http://dx.doi.org/10.1002/hep.23711">[More Information]</a>

van der Poorten, D., Shahidi, M., Tay, E., Sessa, J., Tran, K., McLeod, D., Milliken, J., Ho, V., Hebbard, L., Douglas, M., George, J. (2010). Hepatitis C Virus Induces the Cannabinoid Receptor 1. *PLoS One*, 5(9), 1-10. <a href="http://dx.doi.org/10.1371/journal.pone.0012841">[More Information]</a>

Mahady, S., George, J. (2010). How to Treat: Hepatitis C infection. *Australian Doctor*, , 1-6.

Ahlenstiel, G., Booth, D., George, J. (2010). IL28B in hepatitis

C virus infection: translating pharmacogenomics into clinical practice. *Journal of Gastroenterology and Hepatology*, 45(9), 903-910. <a href="http://dx.doi.org/10.1007/s00535-010-0287-4">[More Information]</a>

Pattullo, V., George, J. (2010). Managing the Patient with Chronic Viral Hepatitis Receiving Chemotherapy. In Monica Robotin, Ian Olver, Afaf Girgis (Eds.), *When Cancer Crosses Disciplines: A Physicians Handbook*, (pp. 813-832). London: Imperial College Press. <a href="http://dx.doi.org/10.1142/9781848163652\_0032">[More Information]</a>

Bhala, N., Usherwood, T., George, J. (2010). Nichtalkoholische Fettlebererkrankung [Non-alcoholic fatty liver]. *Praxis*, 99(3), 187-189. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list\_uids=20127639">[More Information]</a>

Grebely, J., Petoumenos, K., Hellard, M., Matthews, G., Suppiah, V., Applegate, T., Yeung, B., Marks, P., Rawlinson, W., Lloyd, A., Booth, D., George, J., et al (2010). Potential Role for Interleukin-28B Genotype in Treatment Decision-Making in Recent Hepatitis C Virus Infection. *Hepatology*, 52(4), 1216-1224. <a href="http://dx.doi.org/10.1002/hep.23850">[More Information]</a>

Patterson, S., George, J., Strasser, S., Lee, A., Sievert, W., Nicoll, A., Desmond, P., Roberts, S., Locarnini, S., Bowden, S., et al (2010). Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. *Gut*, 60(2), 247-254. <a href="http://dx.doi.org/10.1136/gut.2010.223206">[More Information]</a>

Hebbard, L., George, J. (2010). The chicken or the egg: adipocytes and hepatic insulin resistance. *Hepatology*, 51(3), 1076-1079. <a href="http://dx.doi.org/10.1002/hep.23580">[More Information]</a>

Robotin, M., Kansil, M., George, J., Howard, K., Tipper, S., Levy, M., Phung, N., Penman, A. (2010). Using a population-based approach to prevent hepatocellular cancer in New South Wales, Australia: effects on health services utilisation. *BMC Health Services Research*, 10, 215-224. <a href="http://dx.doi.org/10.1186/1472-6963-10-215">[More Information]</a>

## 2009

Milner, K., van der Poorten, D., Xu, A., Bugianesi, E., Kench, J., Lam, K., Chisholm, D., George, J. (2009). Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. *Hepatology*, 49(6), 1926-1934. <a href="http://dx.doi.org/10.1002/hep.22896">[More Information]</a>

Smith, B., George, J. (2009). Adipocyte-hepatocyte crosstalk and the pathogenesis of nonalcoholic fatty liver disease. *Hepatology*, 49(5), 1765-1767. <a href="http://dx.doi.org/10.1002/hep.22937">[More Information]</a>

Johnson, N., Sachinwalla, T., Walton, D., Smith, K., Armstrong, A., Thompson, M., George, J. (2009). Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. *Hepatology*, 50(4), 1105-1112. <a href="http://dx.doi.org/10.1002/hep.23129">[More Information]</a>

Robotin, M., Kansil, M., Howard, K., George, J., Tipper, S., Dore, G., Levy, M., Penman, A. (2009). Antiviral therapy for

hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. *Journal of Hepatology*, 50(5), 990-998. <a href="http://dx.doi.org/10.1016/j.jhep.2008.12.022">[More Information]</a>

Booth, M., Dobbins, T., Aitken, R., Denney-Wilson, E., Hardy, L., Okely, A., George, J., Sullivan, D., Cowell, C. (2009). Costs of managing conditions associated with obesity among Australian teenagers. *Journal of Paediatrics and Child Health*, 45(7-8), 448-456. <a href="http://dx.doi.org/10.1111/j.1440-1754.2009.01503.x">[More Information]</a>

van der Poorten, D., Milner, K., George, J. (2009). Effect of adipokines on liver disease in females. In Ichiro Shimizu (Eds.), *Female Hepatology: Impact of female sex against progression of liver disease*, (pp. 191-212). India: Research Signpost.

Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M., Bassendine, M., Spengler, U., Dore, G., Powell, E., Stewart, G., Booth, D., George, J., et al (2009). IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. *Nature Genetics*, 41(10), 1100-1104. <a href="http://dx.doi.org/10.1038/ng.447">[More Information]</a>

Johnson, N., St George, A., George, J. (2009). Impact of lifestyle modification on patients with chronic liver disease. *Hot Topics in viral Hepatitis*, 5(14), 17-22.

St George, A., Bauman, A., Johnston, A., Farrell, G., Chey, T., George, J. (2009). Independent effects of physical activity in patients with nonalcoholic fatty liver disease. *Hepatology*, 50(1), 68-76. <a href="http://dx.doi.org/10.1002/hep.22940">[More Information]</a>

Wang, J., Leclercq, I., Brymora, J., Xu, N., Ramezani-Moghadam, M., London, R., Brigstock, D., George, J. (2009). Kupffer Cells Mediate Leptin-Induced Liver Fibrosis. *Gastroenterology*, 137(2), 713-723. <a href="http://dx.doi.org/10.1053/j.gastro.2009.04.011">[More Information]</a>

Douglas, M., George, J. (2009). Molecular mechanisms of insulin resistance in chronic hepatitis C. *World Journal of Gastroenterology*, 15(35). <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list\_uids=19764085">[More Information]</a>

Bhala, N., Usherwood, T., George, J. (2009). Non-alcoholic fatty liver disease. *BMJ: British Medical Journal*, 339(b2474), 513-514. <a href="http://dx.doi.org/10.1136/bmj.b2474">[More Information]</a>

George, J., Robotin, M. (2009). Overview: Hepatocellular carcinoma - the future starts now. *Cancer Forum*, 33(2), 83-87.

Phung, T., Pera, N., Farrell, G., Leclercq, I., Hou, J., George, J. (2009). Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis. *International Journal of Molecular Medicine*, 24, 171-180. <a href="http://dx.doi.org/10.3892/ijmm\_00000220">[More Information]</a>

Milner, K., Chisholm, D., George, J. (2009). The many faces of hepatitis C: liver disease and type 2 diabetes. *Hepatology*, 50(3), 668-670. <a href="http://dx.doi.org/10.1002/hep.23117">[More Information]</a>

Van Hazel, G., Pavlakis, N., Goldstein, D., Olver, I., Tapner, M., Price, D., Bower, G., Briggs, G., Rossleigh, M., Taylor, D., George, J. (2009). Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by

Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy. *Journal of Clinical Oncology*, 27(25), 4089-4095. <a href="http://dx.doi.org/10.1200/JCO.2008.20.8116">[More Information]</a>

## 2008

Poustchi, H., Mohamadkhani, A., Bowden, S., Montazeri, G., Ayres, A., Revill, P., Farrell, G., Locarnini, S., George, J., Malekzadeh, R. (2008). Clinical significance of precore and core promoter mutations in genotype D hepatitis B-related chronic liver disease. *Journal of Viral Hepatitis*, 15(10), 753-760. <a href="http://dx.doi.org/10.1111/j.1365-2893.2008.00998.x">[More Information]</a>

van der Poorten, D., George, J. (2008). Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. *Clinics in Liver Disease*, 12(4), 805-824. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list\_uids=18984468">[More Information]</a>

St George, A., Bauman, A., Johnston, A., Farrell, G., Chey, T., George, J. (2008). Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. *Hepatology*, 24(3), 399-407. <a href="http://dx.doi.org/10.1111/j.1440-1746.2008.05694.x">[More Information]</a>

George, J., Talley, N., Segal, I., Weltman, M. (2008). Evaluating abnormal liver tests. In N Talley, I Segal, M Weltman (Eds.), *Gastroenterology and Hepatology: a clinical handbook*, (pp. 316-326). Australia: Elsevier.

Cua, I., Hui, J., Kench, J., George, J. (2008). Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. *Hepatology*, 48(3), 723-731. <a href="http://dx.doi.org/10.1002/hep.22392">[More Information]</a>

Poustchi, H., Negro, F., Hui, J., Cua, I., Brandt, L., Kench, J., George, J. (2008). Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. *Journal of Hepatology*, 48(1), 28-34. <a href="http://dx.doi.org/10.1016/j.jhep.2007.07.026">[More Information]</a>

Cua, I., George, J. (2008). Insulin resistance, adipocytokines and HCV infection: A missing link? *Hepatology*, 47, 760-761.

George, J., Liddle, C. (2008). Nonalcoholic fatty liver disease: Pathogenesis and potential for nuclear receptors as therapeutic targets. *Molecular Pharmaceutics*, 5(1), 49-59. <a href="http://dx.doi.org/10.1021/mp700110z">[More Information]</a>

van der Poorten, D., George, J. (2008). Nonalcoholic steatohepatitis is frequently accompanied by metabolic diseases: Reply to the Editor. *Hepatology*, 48(5), 1729. <a href="http://dx.doi.org/10.1002/hep.22568">[More Information]</a>

Johnson, N., Walton, D., Sachinwalla, T., Thompson, C., Smith, K., Ruell, P., Stannard, S., George, J. (2008). Noninvasive assessment of hepatic lipid composition: advancing understanding and management of fatty liver disorders. *Hepatology*, 47, 1513-1523. <a href="http://dx.doi.org/10.1002/hep.22220">[More Information]</a>

van der Poorten, D., Kenny, D., George, J. (2008). Prevalence of and risk factors for hepatitis C in Aboriginal and non-Aboriginal adolescent offenders. *Medical Journal of Australia*, 188(10), 610-614. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve">

eve&db=pubmed&dopt=Abstract&list\_uids=18484939">[More Information]</a>

Robotin, M., George, J., Supramaniam, R., Sitas, F., Penman, A. (2008). Preventing primary liver cancer: how well are we faring towards a national hepatitis B strategy? *Medical Journal of Australia*, 188(6), 363-365. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list\_uids=18341462">[More Information]</a>

Johnson, N., Sachinwalla, T., George, J. (2008). Reply: In Vitro Proton Magnetic Resonance Spectroscopy of Liver Tissue Informs In Vivo Hepatic Proton Magnetic Resonance Spectroscopy Studies. *Hepatology*, 48(3), 1016-1017. <a href="http://dx.doi.org/10.1002/hep.22494">[More Information]</a>

Wang, J., Brymora, J., George, J. (2008). Roles of adipokines in liver injury and fibrosis. *Expert Review of Gastroenterology and Hepatology*, 2(1), 47-57. <a href="http://dx.doi.org/10.1586/17474124.2.1.47">[More Information]</a>

George, J., Denney-Wilson, E., Okely, A., Hardy, L., Aitken, R. (2008). The population distributions, upper normal limits and correlations between liver tests among Australian adolescents. *Journal of Paediatrics and Child Health*, 44(10), 579-585. <a href="http://dx.doi.org/10.1111/j.1440-1754.2008.01386.x">[More Information]</a>

Booth, M., George, J., Denney-Wilson, E., Okely, A., Hardy, L., Aitken, R., Dobbins, T. (2008). The population prevalence of adverse concentrations and associations with adiposity of liver tests among Australian adolescents. *Journal of Paediatrics and Child Health*, 44(12), 686-691. <a href="http://dx.doi.org/10.1111/j.1440-1754.2008.01407.x">[More Information]</a>

Yan, K., Guirgis, M., Dinh, T., George, J., Dev, A., Lee, A., Zekry, A. (2008). Treatment responses in Asians and Caucasians with chronic hepatitis C infection. *World Journal of Gastroenterology*, 14(21), 3416-3420. <a href="http://dx.doi.org/10.3748/wjg.14.3416">[More Information]</a>

van der Poorten, D., Milner, K., Hui, J., Hodge, A., Trenell, M., Kench, J., London, R., Peduto, A., Chisholm, D., George, J. (2008). Visceral fat: A key mediator of steatohepatitis in metabolic liver disease. *Hepatology*, 48(2), 449-457. <a href="http://dx.doi.org/10.1002/hep.22350">[More Information]</a>

## 2007

van der Poorten, D., Kenny, D., George, J. (2007). A new upper limit for alanine aminotransferase and risk factors for raised alt and hepatitis C in adolescents: a study of 439 male adolescent offenders on community orders. *Journal of Gastroenterology and Hepatology*, 22(Supplement 3), A344-A344.

Teoh, N., George, J. (2007). Abnormal Liver Function Tests. In N Talley, I Segal, M Weltman (Eds.), *Gastroenterology and Hepatology: a clinical handbook*. Australia: Elsevier.

Angulo, P., George, J., Marchesini, G., Bugianesi, E., Farrell, G., Day, C. (2007). Author's reply: Non-invasive markers of advanced histology in nonalcoholic fatty liver disease. *Gastroenterology*, 133(4), 1377-1378.

van der Poorten, D., George, J. (2007). Current and novel therapies for the treatment of nonalcoholic steatohepatitis. *Hepatology International*, 1(3), 343-354. <a href="http://dx.doi.org/10.1007/s12072-007-9011-8">[More Information]</a>

Cua, I., Hui, J., Bandara, P., Kench, J., Farrell, G., McCaughan, G., George, J. (2007). Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. *Hepatology*, 46(1), 66-73. <a href="http://dx.doi.org/10.1002/hep.21703">[More Information]</a>

van der Poorten, D., Kenny, D., Butler, T., George, J. (2007). Liver disease in adolescents: A cohort study of high-risk individuals. *Hepatology*, 46(6), 1750-1758. <a href="http://dx.doi.org/10.1002/hep.21918">[More Information]</a>

Razali, K., Thein, H., Bell, J., Cooper-Stanbury, M., Dolan, K., Dore, G., George, J., Kaldore, J., Karvelas, M., Li, J., Weltman, M., et al (2007). Modelling the hepatitis C virus epidemic in Australia. *Drug and Alcohol Dependence*, 91(39509), 228-235. <a href="http://dx.doi.org/10.1016/j.drugalcdep.2007.05.026">[More Information]</a>

London, R., George, J. (2007). Pathogenesis of NASH: Animal Models. *Clinics in Liver Disease*, 11(1), 55-74. <a href="http://dx.doi.org/10.1016/j.cld.2007.02.010">[More Information]</a>

Cua, I., George, J. (2007). Reply. *Hepatology*, 46(6), 2051. <a href="http://dx.doi.org/10.1002/hep.22058">[More Information]</a>

Angulo, P., Hui, J., Marchesini, G., Bugianesi, E., George, J., Farrell, G., Enders, F., Saksena, S., Burt, A., Bida, J., Kench, J., et al (2007). The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. *Hepatology*, 45(4), 846-854. <a href="http://dx.doi.org/10.1002/hep.21496">[More Information]</a>

## 2006

George, J. (2006). Angiopoietin-like proteins: Another player in the metabolic field. *Journal of Hepatology*, 44(4), 832-834. <a href="http://dx.doi.org/10.1016/j.jhep.2006.01.010">[More Information]</a>

Bugianesi, E., Marchesini, G., Gentilecore, E., Cua, I., Vanni, E., Rizzetto, M., George, J. (2006). Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. *Hepatology*, 44(6), 1648-1655. <a href="http://dx.doi.org/10.1002/hep.21429">[More Information]</a>

Salmond, S., George, J., Strasser, S., Batey, R. (2006). Hep573 study of complementary medicine for chronic hepatitis C. *Journal Of Clinical Virology*, 36(Supplement 2), S134-S135.

Chitturi, S., George, J. (2006). Hepatitis C and overweight. *Hot Topics in viral Hepatitis*, 2, 15-21.

Cua, I., George, J. (2006). Interpretation of abnormal liver tests in patients with diabetes. *Diabetes Management Journal*, 14, 30-31.

Cua, I., George, J. (2006). Interpretation of abnormal liver tests in patients with diabetes. *Diabetes Management Journal*, 14, 30.

Cua, I., Hui, J., Bandara, P., Kench, J., McCaughan, G., George, J. (2006). Is insulin resistance and liver injury in chronic hepatitis C associated with virus-specific alteration in the levels of serum adipocytokines? *Journal of Gastroenterology and Hepatology*, 21, A22-A22.

St George, A., Johnston, A., Bauman, A., Iverson, D., Tapsell, L., McCaughan, G., Strasser, S., McGrath, L., Green, J., Farrell, G., George, J. (2006). Lifestyle intervention in early liver disease: metabolic changes at 3 months. *Journal of*

Cua, I., Kwan, V., Henriquez, M., Kench, J., George, J. (2006). Long term suppressive therapy with pegylated interferon for chronic hepatitis C associated membranoproliferative glomerulonephritis. *Gut*, 55(10), 1521-1522. <a href="http://dx.doi.org/10.1136/gut.2006.094508">[More Information]</a>

Leandro, G., Mangia, A., Hui, J., Fabris, P., Rubbia-Brandt, L., Colloredo, G., Adinolfi, L., Asselah, T., Jonsson, J., Smedile, A., George, J., et al (2006). Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. *Gastroenterology*, 130(6), 1636-1642. <a href="http://dx.doi.org/10.1053/j.gastro.2006.03.014">[More Information]</a>

Wang, J., Batey, R., George, J. (2006). Role of ethanol in the regulation of hepatic stellate cell function. *World Journal of Gastroenterology*, 12(43), 6926-6932. <a href="http://dx.doi.org/10.3748/wjg.v12.i43.6926">[More Information]</a>

Poustchi, H., George, J., Farrell, G. (2006). The efficacy of a liver cancer screening program on cancer detection and patient survival. *Journal of Gastroenterology and Hepatology*, 21, A52-A52.

## 2005

Helbig, K., George, J., Beard, M. (2005). A novel I-TAC promoter polymorphic variant is functional in the presence of replicating HCV in vitro. *Journal Of Clinical Virology*, 32(2), 137-143. <a href="http://dx.doi.org/10.1016/j.jcv.2004.10.001">[More Information]</a>

Bandara, P., George, J., McCaughan, G., Naidoo, D., Lux, O., Salonikas, C., Kench, J., Byth Wilson, K., Farrell, G. (2005). Antioxidant levels in peripheral blood, disease activity and fibrotic stage in chronic hepatitis C. *Liver International*, 25(3), 518-526. <a href="http://dx.doi.org/10.1111/j.1478-3231.2005.01049.x">[More Information]</a>

Perry, J., Poustchi, H., George, J., Farrell, G., McCaughan, G., Strasser, S. (2005). Current approaches to the diagnosis and management of hepatocellular carcinoma. *Clinical and Experimental Medicine*, 5(1), 1-13. <a href="http://dx.doi.org/10.1007/s10238-005-0058-3">[More Information]</a>

Adams, L., Bulsara, M., Rossi, E., DeBoer, B., Speers, D., George, J., Kench, J., Farrell, G., McCaughan, G., Jeffrey, G. (2005). Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. *Clinical Chemistry*, 51(10), 1867-1873. <a href="http://dx.doi.org/10.1373/clinchem.2005.048389">[More Information]</a>

Kumar, U., Farrell, G., Kench, J., George, J. (2005). Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. *Journal of Gastroenterology and Hepatology*, 20(9), 1395-1400. <a href="http://dx.doi.org/10.1111/j.1440-1746.2005.04007.x">[More Information]</a>

Dela Pena, A., Leclercq, I., Field, J., George, J., Jones, B., Farrell, G. (2005). NF-kappa B activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. *Gastroenterology*, 129(5), 1663-1674. <a href="http://dx.doi.org/10.1053/j.gastro.2005.09.004">[More Information]</a>

Cua, I., George, J. (2005). Non-alcoholic fatty liver disease. *British Journal of Hospital Medicine*, 66(2), 106-111. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retri

eve&db=pubmed&dopt=Abstract&list\_uids=15739708">[More Information]</a>

Hui, J., George, J. (2005). Reply: Adiponectin â€“ Tipping the scales from NAFLD to NASH. *Gastroenterology*, 128(2), 513-513. <a href="http://dx.doi.org/10.1053/j.gastro.2004.09.093">[More Information]</a>

Hui, J., George, J. (2005). Reply: Reduced plasma adiponectin: central obesity as an underestimated causative risk factor. *Hepatology*, 41, 401-402. <a href="http://dx.doi.org/10.1002/hep.20546">[More Information]</a>

## 2004

Hui, J., Hodge, A., Farrell, G., Kench, J., Kriketos, A., George, J. (2004). Beyond Insulin Resistance In Nash: Tnf-Alpha Or Adiponectin? *Hepatology*, 40(1), 46-54. <a href="http://dx.doi.org/10.1002/hep.20280">[More Information]</a>

Coverdale, S., Khan, M., Byth Wilson, K., Lin, R., Weltman, M., George, J., Samarasinghe, D., Liddle, C., Farrell, G., Kench, J., Crewe, E. (2004). Effects Of Interferon Treatment Response On Liver Complications Of Chronic Hepatitis C: 9-Year Follow-Up Study. *American Journal of Gastroenterology*, 99(4), 636-644. <a href="http://dx.doi.org/10.1111/j.1572-0241.2004.04085.x">[More Information]</a>

McCaughan, G., George, J. (2004). Fibrosis Progression In Chronic Hepatitis C Virus Infection. *Gut*, 53(3), 318-321. <a href="http://dx.doi.org/10.1136/gut.2003.026393">[More Information]</a>

Hui, J., Farrell, G., Kench, J., George, J. (2004). High sensitivity C-reactive protein values do not reliably predict the severity of histological change in NAFLD. *Hepatology*, 39(5), 1458-1459. <a href="http://dx.doi.org/10.1002/hep.20223">[More Information]</a>

Sud, A., Hui, J., Farrell, G., Bandara, P., Kench, J., Fung, C., Lin, R., Samarasinghe, D., Liddle, C., McCaughan, G., George, J. (2004). Improved Prediction Of Fibrosis In Chronic Hepatitis C Using Measures Of Insulin Resistance In A Probability Index. *Hepatology*, 39(5), 1239-1247. <a href="http://dx.doi.org/10.1002/hep.20207">[More Information]</a>

Kwan, V., George, J. (2004). Liver Disease Due To Parenteral And Enteral Nutrition. *Clinics in Liver Disease*, 8(4), 893-913, ix-x.

Chitturi, S., Farrell, G., George, J. (2004). Non-Alcoholic Steatohepatitis In The Asia-Pacific Region: Future Shock? *Journal of Gastroenterology and Hepatology*, 19(4), 368-374. <a href="http://dx.doi.org/10.1111/j.1440-1746.2003.03252.x">[More Information]</a>

Zeuzem, S., Diago, M., Gane, E., Reddy, K., Pockros, P., Prati, D., Shiffman, M., Farci, P., Gitlin, N., O'Brien, C., George, J., et al (2004). Peginterferon Alfa-2a (40 Kilodaltons) and Ribavirin in Patients With Chronic Hepatitis C and Normal Aminotransferase Levels. *Gastroenterology*, 127(6), 1724-1732. <a href="http://dx.doi.org/10.1053/j.gastro.2004.09.050">[More Information]</a>

## 2003

Shao, R., Shi, Z., Gotwals, P., Koteliansky, V., George, J., Rockey, D. (2003). Cell and molecular regulation of endothelin-1 production during hepatic wound healing. *Molecular Biology of the Cell*, 14(6), 2327-2341. <a



href="http://dx.doi.org/10.1091/mbc.02-06-0093">[More Information]</a>

Coverdale, S., Samarasinghe, D., Lin, R., Kench, J., Byth Wilson, K., Khan, M., Crewe, E., Liddle, C., George, J., Farrell, G. (2003). Changes in Antipyrine Clearance and Platelet Count, but Not Conventional Liver Tests, Correlate With Fibrotic Change in Chronic Hepatitis C: Value for Predicting Fibrotic Progression. *American Journal of Gastroenterology*, 98(6), 1384-1390. <a href="http://dx.doi.org/10.1111/j.1572-0241.2003.07468.x">[More Information]</a>

Kumar, D., Wallington-Beddoe, C., George, J., Lin, R., Samarasinghe, D., Liddle, C., Farrell, G. (2003). Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hepatitis c in a clinic setting. *Medical Journal of Australia*, 178(6), 267-271.

Hui, J., Sud, A., Farrell, G., Bandara, P., Byth Wilson, K., Kench, J., McCaughan, G., George, J. (2003). Insulin resistance is associated with chronic Hepatitis C and virus infection fibrosis progression. *Gastroenterology*, 125(6), 1695-1704. <a href="http://dx.doi.org/10.1053/j.gastro.2003.08.032">[More Information]</a>

Chitturi, S., George, J. (2003). Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. *Current Gastroenterology*, 5(1), 18-25. <a href="http://dx.doi.org/10.1007/s11894-003-0005-y">[More Information]</a>

George, J. (2003). Invited Book Review "Hepatitis C: An Australian perspective. Eds. N Crofts, G Dore and S Locarnini. *Internal Medicine Journal*, 33(1), 64-64.

George, J., Pera, N., Phung, T., Leclercq, I., Hou, J., Farrell, G. (2003). Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. *Journal of Hepatology*, 39(5), 756-764. <a href="http://dx.doi.org/10.1016/S0168-8278(03)00376-3">[More Information]</a>

Hui, J., Kench, J., Chitturi, S., Sud, A., Farrell, G., Blyth, K., Hall, P., Khan, M., George, J. (2003). Long term outcomes of cirrhosis in nonalcoholic steatohepatitis compares with hepatitis c. *Hepatology*, 38(2), 420-427. <a href="http://dx.doi.org/10.1053/jhep.2003.50320">[More Information]</a>

Perry, J., Strasser, S., George, J., Farrell, G., McCaughan, G. (2003). Pharmacotherapy of hepatocellular carcinoma. *Expert Opinion on Pharmacotherapy*, 4(12), 2175-2185. <a href="http://dx.doi.org/10.1517/14656566.4.12.2175">[More Information]</a>

Chitturi, S., Farrell, G., George, J. (2003). Reply: Iron and HFE mutations in nonalcoholic steatohepatitis: Innocent bystanders or accessories to the crime? *Gastroenterology*, 125(2), 616-616.

Lee, D., Chitturi, S., Kench, J., George, J., Fuller, S., Bradstock, K., Lin, R., Wong, K., Young, N. (2003). Transjugular liver biopsy effecting changes in clinical management. *Journal of Medical Imaging and Radiation Oncology*, 47(2), 117-120. <a href="http://dx.doi.org/10.1046/j.0004-8461.2003.01138.x">[More Information]</a>

## 2002

Hui, J., George, J., Liddle, C., Lin, R., Samarasinghe, D., Crewe, E., Farrell, G. (2002). Changes in Serum Albumin During Treatment of Chronic Hepatitis B With Lamivudine: Effects of Response and Emergence of Drug Resistance. *American Journal of Gastroenterology*, 97(4), 1003-1009. <a href="http://dx.doi.org/10.1016/S0002-9270(02)03977-1">[More Information]</a>

Singal, D., George, J. (2002). Chronic hepatitis C. *Australian Doctor*.

Teoh, N., George, J. (2002). Evaluating patients who have abnormal liver tests. *Medicine Today*, 3(10), 58-67.

Chitturi, S., George, J., Ranjithkumar, S., Kench, J., Benson, W. (2002). Exchange Transfusion for Severe Intrahepatic Cholestasis Associated With Sickle Cell Disease. *Journal of Clinical Gastroenterology*, 35(4), 362-363. <a href="http://dx.doi.org/10.1097/00004836-200210000-00019">[More Information]</a>

Alonso, C., George, J., Pesce, C., Bissell, D., Kornblihtt, A. (2002). Fibronectin transcription in liver cells: promoter occupation and function in sinusoidal endothelial cells and hepatocytes. *Biochemical and Biophysical Research Communications*, 295(5), 1077-1084. <a href="http://dx.doi.org/10.1016/S0006-291X(02)00802-1">[More Information]</a>

Hui, J., Kench, J., Farrell, G., Lin, R., Samarasinghe, D., Liddle, C., Byth, K., George, J. (2002). Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. *Journal of Gastroenterology and Hepatology*, 17(8), 873-881. <a href="http://dx.doi.org/10.1046/j.1440-1746.2002.02813.x">[More Information]</a>

Chitturi, S., Le, V., Kench, J., Loh, C., George, J. (2002). Gliclazide-Induced Acute Hepatitis with Hypersensitivity Features. *Digestive Diseases and Sciences*, 47(5), 1107-1110. <a href="http://dx.doi.org/10.1023/A:1015002526879">[More Information]</a>

Hui, J., Farrell, G., Lin, R., Samarasinghe, D., Liddle, C., George, J., Kench, J., Byth, K. (2002). Hepatic Steatosis in Chronic Hepatitis C Infection. *Journal of Gastroenterology and Hepatology*, 17(8), 873-881.

Kumar, S., Farrell, G., Fung, C., George, J. (2002). Hepatitis C Virus Genotype 3 is Cytopathic to Hepatocytes: Reversal of Hepatic Steatosis after Sustained Therapeutic Response. *Hepatology*, 36(5), 1266-1272. <a href="http://dx.doi.org/10.1053/jhep.2002.36370">[More Information]</a>

Chitturi, S., George, J. (2002). Hepatotoxicity of Commonly Used Drugs: nonsteroidal Anti-Inflammatory Drugs, Antihypertensives, Antidiabetic Agents, Anticonvulsants, Lipid-Lowering Agents, Psychotropic Drugs. *Seminars in Liver Disease*, 22(2), 169-183. <a href="http://dx.doi.org/10.1055/s-2002-30102">[More Information]</a>

Chitturi, S., Weltman, M., Farrell, G., McDonald, D., Liddle, C., Samarasinghe, D., Lin, R., Abeygunasekera, S., George, J. (2002). HFE Mutations, Hepatic Iron, and Fibrosis: Ethnic-Specification Association of NASH with C282Y but not with Fibrotic Severity. *Hepatology*, 36(1), 142-149. <a href="http://dx.doi.org/10.1053/jhep.2002.33892">[More Information]</a>

Chitturi, S., Abeygunasekera, S., Farrell, G., Holmes-Walker, J., Hui, J., Fung, C., Karim, R., Lin, R., Samarasinghe, D., Liddle, C., Weltman, M., George, J. (2002). NASH and Insulin Resistance: Insulin Hypersecretion and Specific Association with the Insulin Resistance Syndrome. *Hepatology*, 35(2), 373-379. <a href="http://dx.doi.org/10.1053/jhep.2002.30692">[More Information]</a>

Chitturi, S., Farrell, G., Frost, L., Kriketos, A., Lin, R., Liddle, C., Samarasinghe, D., George, J. (2002). Serum Leptin in NASH Correlates with Hepatic Steatosis but not Fibrosis: A Manifestation of Lipotoxicity? *Hepatology*, 36(2), 403-409. <a href="http://dx.doi.org/10.1053/jhep.2002.34738">[More Information]</a>

Information]

Farrell, G., Phung, T., Ip, E., Dela Pena, A., Robertson, G., Pera, N., George, J., Leclercq, I. (2002). Sources of oxidant stress in fatty liver disorders. Interactive mechanisms, and relevance to fibrosing steatohepatitis. *AASLD Single Topic Conference NASH* "Nonalcoholic Steatohepatitis".

Wong, V., Fu, A., George, J., Cheung, N. (2002). Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. *Clinical Endocrinology*, 56(6), 793-798. <http://dx.doi.org/10.1046/j.1365-2265.2002.01553.x>[More Information]

## 2001

Chitturi, S., Hui, J., Salisbury, E., Mitchell, D., George, J. (2001). Abdominal pain in an intrauterine contraceptive device user. *Postgraduate Medical Journal*, 77, 602-610.

Phung, T., Farrell, G., Robertson, G., George, J. (2001). Antioxidant therapy with vitamin E ameliorates hepatic fibrosis in MCDD-associated NASH. *Asia Pacific Digestive Week 2001*, : World Scientific Publishing.

Chitturi, S., Abeygunasekera, S., Fung, C., Samarasinghe, D., Lin, R., McDonald, D., Weltman, M., Farrell, G., George, J. (2001). Haemochromatosis gene mutations, hepatic iron content and nonalcoholic steatohepatitis. *Hepatology*, 19, 1768-1778.

Leclercq, I., George, J., Farrell, G., Robertson, G., Field, J. (2001). Leptin is an essential mediator of hepatic fibrogenesis and liver regeneration in chronic CCl4-induced liver injury. *Asia Pacific Digestive Week 2001*, : World Scientific Publishing.

Pera, N., Phung, H., Leclercq, I., Farrell, G., George, J. (2001). Oxidative stress and the evolution of hepatic fibrogenesis in a rodent model of nonalcoholic steatohepatitis. *Asia Pacific Digestive Week 2001*, : World Scientific Publishing.

Coverdale, S., Samarasinghe, D., Lin, R., Liddle, C., George, J., Farrell, G., Kench, J., Byth, K., Khan, M., Crewe, E. (2001). Prediction of histological progression in chronic hepatitis C. *Asia Pacific Digestive Week 2001*, : World Scientific Publishing.

George, J., Hui, J., Farrell, G., Lin, R., Samarasinghe, D., Kench, J. (2001). Predictors for steatosis and fibrosis in chronic hepatitis C. *Journal of Hepatology*, 34, 153-153.

Farrell, G., Liddle, C., Samarasinghe, D., Lin, R., George, J., Chitturi, S., Frost, L. (2001). Serum Leptin: An independent predictor of hepatic steatosis but not fibrotic severity in nonalcoholic steatohepatitis. *Hepatology*, 34, 752-752.

Pera, N., Phung, H., Leclercq, I., Farrell, G., George, J. (2001). The role of oxidative stress in the evolution of hepatic fibrogenesis in a rodent model of nonalcoholic steatohepatitis. *The American Association for the Study of Liver Diseases 52nd Annual Meeting*, : World Scientific Publishing.

Pera, N., Phung, H., Leclercq, I., Farrell, G., George, J. (2001). This role of oxidative stress in the evolution of hepatic fibrogenesis in a rodent model of nonalcoholic steatohepatitis. *Hepatology*, 34, 1132-1132.

Bissell, D., Roulot, D., George, J. (2001). Transforming growth factor B and the liver. *Hepatology*, 34(5), 859-867.

Phung, T., Farrell, G., Robertson, G., George, J. (2001). Vitamin E but not glutathione precursors ameliorates hepatic fibrosis in experimental NASH. *Journal of Gastroenterology and Hepatology*, 16.

Phung, T., Farrell, G., Robertson, G., George, J. (2001). Vitamin E but not glutathione precursors inhibits hepatic fibrosis in experimental NASH exhibiting oxidative stress and mitochondrial abnormalities. *Hepatology*, 34, 756-756.